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4. Abstract??
 
Serum osteocalcin (OC) is an osteoblast-derived protein and an established biomarker of bone turnover 
and formation. Previous studies have focused on its role as a predictor of fractures and only recently, OC 
has been recognized as an endocrine factor potentially regulating glucose tolerance and energy 
metabolism. Uncarboxylated OC has been shown to induce expression of adiponectin, insulin, and 
markers of pancreatic islet cell proliferation in mice while only few studies have evaluated these 
interactions in humans.   
The association of OC and glucose homeostasis has been retrospectively explored, in multiple post hoc 
analyses and in cohorts impacted by multiple confounding factors including chronic metabolic 
conditions, cardiovascular (CV) co-morbidities, and diabetes. None of the studies have addressed the 
alleged association in apparently healthy young adults or those with early signs of insulin resistance but 
no diabetes. In addition, the timing, duration and magnitude of serum OC response to glucose loads in 
any population remain unknown. 
Adult subjects born with very low birth weight (VLBW) present with significant, simultaneous 
impairments in skeletal health such as lower bone mineral density (BMD), and progressively worsening 
glucose tolerance in early adulthood. This provides an opportunity to further explore the recently 
suggested bidirectional regulative pathway between glucose and bone metabolism. The thesis studies 
evaluated whether early signs of insulin resistance and impaired glucose tolerance in early adulthood in 
an apparently healthy VLBW cohort, in obese young adults without diabetes, or their controls, could 
demonstrate if and how the changes in bone and glucose metabolism are associated and whether these 
changes are reflected in serum OC concentrations and its degree of carboxylation. Furthermore, normal 
paediatric reference ranges and their independent determinants for serum total, carboxylated and urinary 
OC were to be established. 
No association between parameters of glucose homeostasis and OC were established at any time-point. 
Energy metabolism evidently influences the key parameters of bone turnover but the direct role of insulin 
as the mediator of these changes needs further investigations. Contradictory to the preclinical rodent data, 
serum OC appears to be associated with long-term glucose regulation, if any, whereas acute changes 
during OGTT may be mediated via other mechanisms. 
Age, height and weight, and parathyroid hormone (PTH) and puberty, are independent determinants of 
serum and urinary OC levels during childhood and adolescence.  Circulating OC reflects more pubertal 
growth status than instant grade of bone mineralisation and thus its validity, similar to other bone turnover 
markers, as a determinant of bone status in healthy individuals is limited. 
With greater discrimination of the different forms of osteocalcin present in circulation and inclusion of 
multiple measures of bone turnover and glucose homeostasis, evidence currently does not support OC as 
a protein critical to the regulation of energy metabolism. OC is still a prodigious marker of bone turnover 
and for monitoring of the effect treatments targeting impaired bone metabolism, especially in adults. ? 
? ?
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5. Tiivistelmä??
Seerumin osteokalsiini on luusolujen tuottama endokriininen merkkiaine, joka kuvastaa luuston 
aineenvaihduntaa. Tuoreissa tutkimuksissa on havaittu osteokalsiinilla olevan mahdollisesti yhteyttä 
myös energia-aineenvaihduntaan. Hiirillä osteokalsiinin karboksyloimaton muoto lisää adiponektiinin ja 
insuliinin eritystä sekä haiman kasvua kuvaavien merkkiaineiden määrää. Näitä piirteitä ei kuitenkaan 
ole juurikaan tutkittu ihmisillä. Yksittäisissä kohorttitutkimuksissa on tutkittu osteokalsiinin ja 
glukoositasapainon yhteyttä. Tutkittavat ovat kuitenkin yleensä kärsineet sairauksista, jotka myös 
vaikuttavat sokeritasapainoon (mm. metabolinen oireyhtymä, diabetes, sydän- ja verisuonisairaudet), ja 
siten tulosten tulkinta on ollut haastavaa. Terveillä nuorilla aikuisilla sokeritasapainon ja osteokalsiinin 
yhteyksiä ei ole tutkittu eikä myöskään ole tutkimustietoa ravinnon tai glukoosi-infuusion vaikutuksesta 
osteokalsiinin eritykseen.  
Pikkukeskosina syntyneillä todetaan varhaisella aikuisiällä täysiaikaisena syntyneitä ikätovereitaan 
matalammat luun mineraalitiheydet ja alentunut insuliiniherkkyys. Väitöskirjassa kartoitettiin luuston ja 
glukoosiaineenvaihdunnan muutosten yhteyttä, sekä osteokalsiinin ja sen karboksyloitumisen vaikutusta, 
insuliiniresistenssiin ja alentuneeseen glukoosinsietoon terveillä pikkukeskosena syntyneillä aikuisilla 
sekä ylipainoisilla nuorilla aikuisilla. Lisäksi tutkimuksissa määriteltiin seerumin osteokalsiinin ja 
karboksyloidun osteokalsiinin sekä virtsan osteokalsiinin normaaliarvot lapsilla ja tutkittiin, mitkä tekijät 
terveillä lapsilla vaikuttavat osteokalsiinin pitoisuuksiin. 
Glukoositasapainoa kuvastavien merkkiaineiden ja luuston osteokalsiinin säätelyn välistä yhteyttä ei 
pystytty osoittamaan tutkituissa kohorteissa. Myöskään glukoosirasituksessa yhteyttä ei voitu todeta 
minkään aikapisteen osalta. Energia-aineenvaihdunnan muutokset vaikuttivat luun muodostuksen 
keskeisiin merkkiaineisiin mutta insuliinin merkitys niitä säätelevänä tekijänä ei saanut vahvistusta. 
Päinvastoin kuin eläinmalleissa, seerumin osteokalsiinilla voi olla yhteys pitkäaikaisen glukoosi-
tasapainon säätelyyn kun taas glukoosirasituksen yhteydessä akuuttiin glukoosiaineenvaihdunnan 
säätelyyn vaikuttavat todennäköisesti muut välittäjämekanismit.   
Lapsuudessa ja nuoruusiässä ikä, pituus ja paino, sekä lisäkilpirauhashormoni ja puberteetti ovat 
itsenäisiä seerumin ja virtsan osteokalsiinipitoisuuksia määritteleviä tekijöitä. Verenkierrossa tavattava 
osteokalsiini kuvastaa enemmän puberteetin aikaista kasvua kuin hetkittäistä luuston mineralisoitumista. 
Siksi sen kuten myös muiden luuston merkkiaineiden merkitys luuston terveydentilan arvioinnissa 
terveillä yksilöillä on rajallinen. 
Tämän väitöskirjahankkeen tulokset eivät tue väitteitä osteokalsiinin erityisestä merkitsevyydestä 
energia-aineenvaihdunnan säätelijänä. Aikuisilla osteokalsiini on silti edelleen hyvä luuston 
aineenvaihdunnan merkkiaine erityisesti arvioitaessa heikentyneeseen luustoon kohdistuvan lääkityksen 
hoitovastetta. 
? ?
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6. Introduction?
Homeostasis (originating from Greek: ?????? homœos, "similar" and ?????? stasis, "standing still") as 
defined already by Claude Bernard in 1865, is the property of a system in which variables are regulated 
so that internal conditions remain stable and relatively constant. Regulation of one organ or a system 
occurs through function-limiting feedback, which has also been recognised as one of the cardinal rules 
of endocrinology while it applies to most physiological functions- a principle positing that different 
organs exert opposite, regulatory effects on the same function or organ1.  
Historically, bone has not been acknowledged to exert any such endocrine functions. Implementation of 
this endocrine concept in the recent studies exploring the effect of bone on glucose and energy 
metabolism has modified our understanding and view of an osteoblast-derived molecule, osteocalcin 
(OC) and its potential role in glucose and energy homeostasis.  
Already in early 1990’s, serum OC was established as a marker of both high bone formation but also 
accelerated bone turnover2. As OC is being specifically expressed by osteoblasts, most of the historical 
studies have focused on the characterisation of OC as a predictor of fractures and solely as a component 
of bone metabolism. Despite many in vitro and in vivo studies over the past decades, the specific function 
of OC remains perplexing. In addition, its presumed receptor yet remains to be identified. Only recently, 
the role of OC as an endocrine factor exerting a significant control on energy metabolism has been 
suggested. However, the presented evidence were mostly, if not solely, described in mice, the animal, 
which represents the renaissance of the study of physiology through genetics. While the applicability of 
these results in a more complex organism such as humans, is questionable, especially viewed from the 
perspective of the field of endocrinology and concept of homeostasis. 
As the evidence regarding the suggested link between OC and energy metabolism in humans was scant 
or equivocal, confounded by the selection of populations with multiple co-morbidities influencing their 
metabolic homeostasis, the concept of bi-directional regulatory role of OC remains controversial, debated 
and undetermined. Thus, the question remains- if the skeleton and the metabolically active bone tissue 
are influenced by the organs, which are not classically affected by it and furthermore, whether the 
skeleton influences them in return instead. 
?
? ?
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7. Review?of?literature?
7.1 Bone?structure?and?anatomical?architecture?
Bone is a dynamic organ containing even a cell type, osteoclast, which is curiously targeting to destroy 
itself, the host3. However, the paradigm of bone biology is relatively new as only since 1950’s the 
subsidiary role of bone as a participant in haematopoiesis or calcium homeostasis additional to its 
structural functions related to mobility, posture or protection of our inner organs and bone marrow, was 
stipulated.  
Anatomically bones can be divided into two main categories, which are produced via two distinct 
processes during foetal development and longitudinal growth4. Intra-membranous ossification, growth 
of the primary or secondary ossification centres, prevails in flat bones such as the skull bones or clavicle. 
The process occurs in condensations with embryonic connective tissue by proliferation and 
differentiation of mesenchymal progenitor cells directly into bone forming cells4. On the other hand, long 
limb bones, with tubular structure, such as the femur or tibia, are dependent on cartilage template and 
endochondral ossification, which occurs in the growth plates located between metaphysis and epiphyses5. 
The epiphyseal growth plate has a crucial role in bone growth and two opposing processes determine its 
thickness: 1) chondrocyte proliferation and hypertrophy, and 2) chondrocyte apoptosis and vascular 
invasion of the growth plate, followed by conversion into primary bone spongiosa6.  
The external parts and the diaphysis of the bone, as most of our skeleton (up to 80%) comprise 
predominantly of cortical bone5. Structurally it consists of dense layers of calcified tissue arranged as 
concentric lamellae forming osteons with a Haversian canal in the middle. In turn, vertebral columns and 
metaphyseal areas, parallel with the epiphysis of long bones, are macroscopically made of trabecular 
bone. Trabecular, or cancellous bone, is a less dense network of calcified trabeculae which represents the 
greatest surface of all bone structures and the metabolically active tissue maintaining the mineral 
homeostasis. Both cortical and trabecular bone are composed by the same bone cells and extracellular 
matrix with its inorganic and organic components; minerals, collagen fibres such as Type I collagen, and 
other non-collagen proteins7.  
 
7.2 Normal?bone?turnover?and?metabolism??
Bone as a tissue has a well-established and regulated metabolic function beyond its structural and 
architectural functionality as it participates in homeostasis by storing and releasing two essential 
minerals, calcium and phosphate7,8. Up to 99% of the body calcium is stored in bone, bound to the bone 
matrix in the form of hydroxyapatite crystals (HAP)9. These small, soluble crystals provide mechanical 
rigidity and load bearing strength to the organic bone matrix but also an accessible reservoir for the 
minerals and other ions such as phosphate10. Phosphorus is an essential element of bone and plays an 
important role in multiple biological processes11. The homeostasis of phosphate is determined by 
modulation of intestinal uptake of dietary phosphate, renal phosphate reabsorption and excretion, and the 
exchange of phosphate between extracellular and bone storage pools12. Maintenance of adequate 
inorganic phosphorus levels is essential for bone matrix mineralisation13, which is required also for 
vascular invasion of the growth plate cartilage, and is delayed or prevented by calcium or phosphorus 
deficiencies6. 
14?
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The composite design of bone defines its strength, which is depending on the structural and material 
components. In order to maintain its structural integrity and fulfil its metabolic function the skeleton 
must also renew bone through a process called remodeling. 
?
7.2.1 Remodeling??
The bone tissue is being dynamically and continuously remodelled by the coupled processes of bone 
resorption by osteoclasts and bone formation by osteoblasts14. Bone remodeling assists in adjusting the 
bone architecture to meet altering mechanical needs and it helps to repair microdamages in bone matrix 
and thus preventing the accumulation of old bone. It consists of a series of sequential, highly regulated 
steps; removal of mineralised bone tissue by mature osteoclasts, which leaves a resorptive cavity to be 
filled by the migrating osteoblast precursors, which later differentiate into mature osteoblasts. 
Osteocytes, the most abundant and long-lived cells within the bone representing the terminal 
differentiation stage of osteoblasts, regulate both remodeling and mineralisation processes while being 
embedded in the mineralised bone matrix consisting of collagen15.  
The bone remodeling cycle begins with activation mediated by cells of the osteoblast lineage but it may 
involve the osteocytes, the lining cells, and the preosteoblasts located in the bone marrow. The cells 
participating in remodeling undergo structural changes in their shape, secrete enzymes, which digest and 
degrade proteins on the bone surface and express a 317 amino acid peptide called receptor activator of 
NF-kappa B ligand (RANKL). The interaction of RANKL with its receptor on osteoclast precursors 
called RANK results in activation, differentiation, and fusion of hematopoietic cells of the osteoclast 
lineage. This RANKL/RANK interaction starts the process of resorption but also confirms the role of 
RANKL in coupled bone resorption and formation. Furthermore, it also prolongs osteoclast survival by 
suppressing apoptosis16 while its own activity is blocked by osteoprotegerin (OPG), which acts as a 
soluble receptor acting as an antagonist, a decoy. OPG is primarily produced by the cells of osteoblast 
lineage and it regulates bone resorption by inhibiting the final osteoclast differentiation and activation 
and by inducing their apoptosis16.  
The entire remodeling process takes place in a coordinated fashion and in distinct places as the bone 
formation only takes place at sites where bone has been recently resorbed17. A complete remodeling cycle 
takes 3-4 months, 10% of all bone tissue at any point in time is being remodeled, every day and 24/7, 
and up to one quarter of trabecular bone is annually being replaced in adults7. Collectively these 
continued remodeling cycles in an adult skeleton lead to replacement of bone tissue every 10 years.  
During a lifetime, there are several diverse phases of bone turnover with either accelerated bone building 
or slow decline in bone mass or bone mineral density (BMD). Growth spurts during periods in childhood 
or puberty lead towards attainment of the maximum bone mass, peak bone mass, in a healthy adult full-
grown skeleton around the age of 20 years18. After having reached the peak bone mass and especially 
after the 40th year of life the resorption overtakes the speed of bone building and the skeleton starts to 
gradually lose bone19,20.  
Skeletal remodeling can be triggered by multiple factors: mechanical forces, bone micro-damage or by 
hormonal, calcium-regulating or sex hormone, even leptin, responses to change in mineral supply. 
Additional factors, which influence remodeling, are listed in Text?box?121: 
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7.2.2 Modeling?
During childhood and adolescence, bones are sculpted by modeling, which allows for the formation of 
new bone at one site and the removal of old bone from another site within the same bone22.? ?These 
independent processes thus occur on different surfaces of the bone (vs. coupled remodeling process)23,24.?
This allows individual bones to grow in size and length, to shift in space or reshape, resulting also in a 
net increase of bone mass. During childhood, bones grow because resorption occurs inside the bone while 
formation of new bone occurs on its outer, periosteal surface. At puberty, the bones get thicker because 
formation can occur on both the peri- and endo-osteal (inner) surfaces.  
 
In a developing foetus, a total of 80% of foetal bone mineralisation occurs during the last trimester of a 
normal pregnancy25. Acquisition of bone mass later in childhood results from bone formation without 
preceding resorption at a particular site. However, also bone resorption takes place during this time even 
if the rapidly occurring bone formation by far exceeds the rate of resorption26. The lengthening and 
widening of the bones and accrual of higher BMD leads to a 30-fold increase in bone mass from infancy 
to adulthood27. There appears to be no relationship between the duration of puberty and accrual of peak 
bone mass28. 
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7.2.3 Hormonal?regulation?of?bone?turnover?
Calcium?and?phosphate?regulating?hormones?
Calcium and phosphate regulating hormones play a vital role in healthy bone metabolism (Figure 1). 
Parathyroid hormone (PTH) maintains the level of calcium and stimulates both resorption and formation 
of bone29. Calcitriol, the hormonally active metabolite of vitamin D (also called 1,25-
dihydroxycholecalciferol or 1,25-dihydroxyvitamin D3, i.e. 1,25 (OH)2D3), stimulates sufficient 
intestinal absorption of calcium and phosphorus while it furthermore also directly affects bone 
metabolism29. The third calcium-regulating hormone, calcitonin, counteracts bone resorption and may 
protect against excessively high levels of calcium, hypercalcaemia. Fibroblast Growth Factor 23 (FGF-
23), a counter-regulatory hormone for 1,25 (OH)2D3,  reduces serum PTH levels via signal transduction 
in the parathyroid gland and contributes to a prolonged negative feedback loop additionally involving 
bone and kidney30,31. 
PTH is produced by four small parathyroid glands adjacent to the thyroid gland. These glands are 
sensitive to rapid changes in calcium concentration: when concentration of calcium decreases even 
marginally, the secretion of PTH immediately increases. In order to conserve calcium, PTH increases 
proximal tubular expression of 25(OH)D 1?-hydroxylase, resulting in increased production of 
1,25(OH)2D3 and, consequently, increased calcium absorption in the gut. PTH similarly enhances 
calcium reabsorption in the distal convoluted tubule32.  PTH also acts directly on the bone to increase 
movement of calcium from bone to extracellular fluid by increasing osteoclastic bone resorption. 
Excessive production of PTH, hyperparathyroidism, usually induced due to a small tumour of the 
parathyroid glands, can lead to bone loss29. PTH hormonally regulates also the plasma phosphate 
concentrations, causing an immediate reduction in phosphate levels via action on handling of phosphate 
in proximal tubule33. Chronic elevated PTH concentrations induce a decrease in serum phosphate, which 
in certain disease conditions may lead to rickets and osteomalacia. 
PTH can exert both anabolic and catabolic effect on bone, stimulation both bone formation as well as 
resorption. The effect of therapeutic, exogenously administrated PTH on bone is dependent on the mode 
of administration: when small amounts of PTH are administered intermittently, bone formation 
predominates and the bone strength increases34. PTH and 1,25(OH)2D3 also regulated remodelling by 
stimulating RANKL secretion35,36.  
The second hormone related to PTH, parathyroid hormone-related protein (PTHrP), typically regulates 
cartilage and bone development in the foetus37 while over-production might indicate malignancy. PTHrP 
acts similar to PTH, i.e. causing excessive bone breakdown and malignant hypercalcaemia38. 
FGF-23, a phosphatonin regulating the phosphate homeostasis, is a 251-amino acid glycoprotein, which 
adjusts the physiological response to dietary phosphate load. Increased oral phosphate intake results in 
increased secretion and higher serum levels of FGF-23, leading to decreased absorption of phosphorus 
from the gut. Its N and C terminals are participating in the hormone’s activity; N-terminal peptide binds 
to its receptor in the tissues and its C-terminal binds to Klotho39. FGF-23 is predominantly expressed in 
bone, in osteocytes40, but it is also expressed in a variety of human and mouse tissues, including brain, 
thymus, small intestine, heart, lung, liver, kidney, thyroid/parathyroid, lymph node, skeletal muscle, 
spleen, skin, stomach, and testis41,42,43,44. FGF-23 causes a decrease in phosphate reabsorption by 
downregulating the sodium phosphate co-transporters in the proximal tubule, leading to phosphaturia 
and hypophosphatemia. It lowers serum levels of active Vitamin D by diminishing the production of 
calcitriol and increasing its catabolism by inhibiting the activity of renal 1?-hydroxylase and stimulating 
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that of 24-hydroxylase, respectively45.The effect of FGF-23 on proximal tubular phosphate reabsorption, 
which requires hours or even days, is independent of PTH and calcitriol46. 
 
Figure?1:??The?role?of?calcium?and?phosphate?(PO4)?regulating?hormones?on?bone??the?PTH/vitamin?D?
or?FGF?23?pathways.?The parathyroid gland detects changes in the level of Ca2+ in blood, leading to 
secretion of PTH. A decrease in circulating calcium stimulates the parathyroid gland to produce and 
release PTH. PTH increases calcium levels in a pleiotropic fashion by stimulating osteoclastic bone 
resorption to release calcium and phosphate, calcium reabsorption and phosphate excretion in the renal 
distal convoluted tubule by downregulating the co-transporters and production of 1,25(OH)2D3 by 1?-
hydroxylase in the kidney, which, in turn, increases intestinal calcium and phosphate absorption. The 
kidney is the principle physiological target, where FGF-23 signalling acts to promote PO4 excretion by 
downregulating co-transporters and inhibiting 1,25(OH)2D3 production, thus preventing Vitamin D-
mediated PO4 absorption in the gut. Serum levels of FGF-23 increase in response to increased serum PO4 
and 1,25(OH)2D, and furthermore, FGF-23 inhibits the production of PTH.  
?
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Calcitonin, also known as thyrocalcitonin, is a 32-amino acid polypeptide produced by parafollicular C-
cells of the thyroid gland47. Calcitonin counteracts the effect of PTH and it can offset bone resorption by 
inactivating osteoclasts48.  This effect may be relatively transient in adults. Calcitonin may be more 
important for maintaining bone development and normal blood calcium levels in early life. Excesses or 
deficiencies of calcitonin in adults do not cause impediments in maintaining blood calcium concentration 
or the strength of the bone, while during periods of mobilisation of calcium, such as pregnancy or 
lactation, calcitonin protects against calcium loss49. Calcitonin has also been clinically utilised as an anti-
resorptive therapy, even if with relatively modest effectiveness, in postmenopausal osteoporosis50.  
Calcitriol, 1,25-(OH)2 vitamin D, is the metabolically active form of Vitamin D. It is produced stepwise 
from 7-dehydroxycholesterol after exposure to the ultraviolet B radiation on the skin which induces the 
production of vitamin D3, cholecalciferol. D3, which can also be obtained from various nutrients such as 
fatty fish or fortified dairy products51, is metabolised in the liver into 25-hydroxyvitamin D (25-OHD or 
calcidiol) prior to its conversion into calcitriol in the kidneys. Presence of calcitriol is essential for 
skeletal growth in infancy and early childhood as it increases supply of essential minerals for bone by 
increasing intestinal absorption of calcium and phosphorus. Deleterious effect on, or impairment of  bone 
metabolism or bone growth, have been described in subjects with low vitamin D levels or in infants born 
to mothers with low maternal vitamin D status during pregnancy52. 
Many individuals need vitamin D supplementation due to inadequate levels derived from exposure to the 
sun. Historically, a need for supplementation has been increasingly rising as people began to live indoors, 
wear clothes, and move further towards northern latitudes where the Sun’s rays are increasingly filtered 
during the winter months, leading to insufficient production of vitamin D in the skin. Deficiency of 
Vitamin D leads to a disease of defective mineralisation, called rickets in children and osteomalacia in 
adults. These conditions can result in bone pain, bowing and deformities of the legs, and fractures. 
Treatment with vitamin D can restore calcium supplies and reduce bone loss53. 
 
Sex?hormones?
Besides the calcium-regulating hormones, also sex hormones are essential for regulation of growth of 
the skeleton and maintenance of the bone mass and its strength. Oestrogen and testosterone both have 
effects on bone in both sexes54 and gonadal failure or dysfunction lead to lower bone mass55. The 
oestrogen produced in children and early puberty induces bone growth while the high concentration at 
the end of puberty stops further growth in height by closing the cartilage plates at the ends of long limb 
bones56.  
Oestrogen acts on both osteoclasts and osteoblasts at all stages in life by inhibiting bone resorption57. 
Consequently, the marked decrease in oestrogen at menopause or withdrawal of oestrogen is associated 
with increased bone remodeling, increased depth of resorption sites and increase in osteoclastogenesis, 
leading to rapid net bone loss58. Oestrogen may also act indirectly by influencing the extra-skeletal 
calcium homeostasis and systemic hormones or by modulating the activity of various cytokines or growth 
hormone59.  
Testosterone is the main circulating androgen in males and it is important for skeletal growth and 
maintenance because of its direct and indirect effects on bone: testosterone inhibits bone resorption but 
it also affects bone formation through stimulation of muscle growth, which in turn puts greater stress on 
the bone, leading to bone formation. In turn, hypogonadal men have been observed to present with an 
accelerated rate of bone turnover and increased fracture risk60. Testosterone is also a source of oestrogen 
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in the male body, including bones, as it is converted into oestradiol via aromatisation. This source of 
oestrogen is important for the male bones as well as for women and both animal and human studies 
suggest that testosterone has a dual mode of action on different bone surfaces with involvement of both 
androgen and oestrogen receptor61. In fact, older men have even higher levels of circulating oestrogen 
than postmenopausal women60. 
 
Other?Important?Hormones?
Growth hormone (GH), also known as somatotropin and secreted from the pituitary gland, is an 
important regulator of skeletal growth62. It acts by stimulating the production of another hormone called 
insulin-like growth factor-1 (IGF-1), which in turn is released into circulation from the liver. GH also 
regulates the local production of IGF-1 in other tissues, in particular in bone, while GH may also directly 
affect the bone62. GH is essential for growth and it accelerates skeletal growth at puberty. Decreased 
production of GH and IGF-1 with age may be responsible for the inability of older individuals to form 
bone rapidly or to replace bone lost by resorption63. The GH/IGF-1 system stimulates both the bone-
resorbing and bone-forming cells, but the dominant effect is on bone formation, thus resulting in an 
increase in bone mass64. 
Thyroid hormones increase the energy production of all body cells, including bone cells. These 
hormones increase the rates of both bone formation and resorption65. Thyroid hormone deficiency can 
induce impaired growth in children, while excessive amounts of it can stimulate resorption and weaken 
the skeleton66. The pituitary hormone that controls the thyroid gland, thyreotropin or thyroid-stimulating 
hormone (TSH), may also have direct effects on bone67. 
Cortisol, the major hormone of the adrenal gland, is a critical regulator of metabolism and is important 
to the body’s ability to respond to even extreme stress and injury68. It has complex effects on the skeleton, 
as small quantities are necessary for normal bone development while larger amounts block bone 
growth69. Synthetic forms of cortisol, glucocorticoids, are used to treat many inflammatory diseases such 
as asthma and arthritis. They can cause bone loss due to both decreased bone formation and increased 
bone resorption, both of which lead to an elevated risk of fractures70 
Moreover, there are other circulating hormones that affect the skeleton as well. Insulin is important for 
bone growth, and the response to other bone growth stimulating factors has been demonstrated to be 
impaired in individuals with insulin deficiency71,72. A recently discovered adipocyte-derived hormone, 
leptin, has also been shown to have effects on bone73,74. The documented, but also, speculated bi-
directional effect of these hormones on bone will be discussed later.  
 
? ?
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7.3 Monitoring?bone?turnover?
Different bone markers and their serum or urine levels reflect different steps of the constantly ongoing, 
coupled bone remodeling (see also section 7.2.1)75. The remodeling cycle consists of three consecutive 
phases: 1) resorption, during which osteoclasts digest old bone; 2) reversal, when mononuclear cells 
appear on the bone surface; and 3) formation, when osteoblasts lay down new bone until the resorbed 
bone has been completely replaced. Resorption probably continues for about 2 weeks, the reversal phase 
may last up to a few weeks, while formation can continue for 4 months until the new bone structural unit 
is completely created. Therefore analysis of several bone markers from the same individuals may provide 
information about different aspects on remodeling activity of the skeleton, its local or systemic regulation 
and status of calcium and/or phosphate homeostasis.  
Biochemical bone turnover markers (BTMs) reflect enzymatic activity of the bone cells, excess products 
from the formation or fragments released during the degradation of matrix components76, 77,78 (Figure?2). 
Circulating proteins or their fragments detectable in serum are either derived from the bone resorption 
process when proteins embedded in the bone matrix are being released, formed during proteolytic activity 
in the blood or reflect the de-novo biosynthesis of the intact proteins while the fragments accumulated in 
the urine are products of catabolism via renal filtration and diverse degradation cascades. Circulating 
BTMs also demonstrate dependence on circadian rhythm, characterised by a decrease during the morning 
hours until noon21. Other factors influencing remodelling (Text?box?1) also affect the levels of BTMs and 
should be taken into account when interpreting the results and potential sources of different and 
potentially changing levels of variable BTMs.  
BTMs are, as per their definition specific bone-derived chemical compounds, which a) can be detected 
in serum, plasma, or urine, b) preferably reflect different dimensions of bone turnover, i.e. resorption, 
formation or combinations of both, and c) reflect the bone metabolic activity in total body at a given 
time-point79.  
BTMs may reflect the dynamics (Text?box?2) and functions (Text?box?3) of many diverse compartments 
of bone 80,81.  
 
 
 
 
 
 
  
? a?part?of?the?matrix?(OC,?osteonectin,?and?osteopontin)?
? precursors? or? degradation? products? of? the? matrix? (pro?collagen? or? cross?links? of?
collagen)?
? matrix?enzymes?(ALP,?tartrate?resistant?acid?phosphatase?(TRAP?5b))?
? signaling?substances?such?as?OC?or?sclerostin??
Text?box?2:?BTMs?per?bone?compartments
Text?box?3:?Different?functions?or?roles?of?BTMs
? mineralised?matrix?(hydroxyapatite,?i.e.?calcium?and?phosphate)?
? non?mineralised?matrix? (collagen,?OC,?matrix?metalloproteinase?enzymes,?osteopontin,?
osteonectin)??
? cellular?components?of?the?matrix?(osteoclasts,?osteoblasts,?and?osteocytes)?
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Some compounds may exert several roles; OC with its alleged hormonal properties is an established part 
of the non-mineralised matrix supporting bone remodeling but also maturation of the mineral phase2. 
Another example is ALP, which is a matrix enzyme involved in initiation of bone mineralisation but also 
a marker of cellular, osteoblast, function83. Many of the markers are also associated with different steps 
in either bone formation or resorption; when the rate of bone metabolism is increased both resorption 
and formation markers will increase to indicate increased bone turnover. For clinical assessment and 
decision-making, monitoring of at least two different markers reflecting different phases or steps of bone 
turnover is recommended. 
 
Figure?2:?Key?bone? turnover?markers? indicating?bone? formation? (pink)?and?bone? resorption? (dark?
red)80,81,82.?
 
Adapted?based?on?reviews?and?text?book?chapters?by?Seibel?(?2000);?Seibel?et?al?(?2002)?and?Hammett?Stabler?
(2004).?H+?indicates?hydrogen?ions,?other?abbreviations?used?for?bone?turnover?markers?are?given?in?section?
7.3.1.?and?7.3.2.?
 
BTMs may be utilised as basis for clinical decisions when monitoring a benign or malignant bone 
condition, (desired rapid) effect of a medication83 but not for diagnosis of bone-related diseases or 
conditions. The use of BTMs could only be considered clinically meaningful if the change on individual 
patient level for a given BTM were greater than expected from normal variability of the marker. In 
general, the least significant change is therefore the minimum change between two successive results in 
an individual that would imply a real biological response. However, in pivotal clinical trials changes on 
population level reflect efficacy while on individual level a lack of change in BTMs might also be a sign 
of reduced adherence to therapy or e.g. limited absorption of orally administered anti-resorptive treatment 
regimens84.  
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7.3.1 Bone?resorption?markers?
BTMs describing degradation of mature type I collagen, such as pyridinoline (PYD) and 
deoxypyridinoline (DPD) crosslinks, are almost solely derived from high turnover bone tissue and not 
affected by degradation of newly produced collagen85.  The telopeptide regions of type I collagen can 
also be assessed with immunoassays by recognising its cross-link free telopeptides81 such as the dynamic 
C-terminal telopeptide (CTX), its extended fragments produced by cathepsin K (ICTP86) or the N-
terminal variant (NTX), which is often being assessed from urine.  The iso-form 5b of the tartrate-
resistant acid phosphatase family (TRAP-5b) has been identified as a BTM, which specifically reflects 
the rate of bone resorption and osteoclast activity87. Additionally bone resorption can be assessed by 
more seldom utilised BTMs such as e.g. hydroxyproline or bone sial protein (BSP). 
 
7.3.2 Bone?formation?markers?
Presence of pro-peptides of type I collagen, or rather its C- (PICP) and N (PINP or P1NP)-terminal ends 
reflect cleaving of peptide processing and formation of collagen. Even if type I collagen is also a 
component of many other tissues, the collagen turnover is more pronounced in bone vs. non-skeletal 
tissues and thus elevated levels of PICP and PINP are generally accepted to reflect increased bone 
formation81.  While most of the commonly assessed BTMs are cleavage products of collagen, bone –
specific alkaline phosphatase (BSAP), the activity of this membrane-bound enzyme can also be used as 
a marker of bone formation. BSAP is expressed in osteoblasts and it is released into circulation during 
bone formation process. The levels of total alkaline phosphatase represents a pool of isoforms but the 
bone-specific BSP as a highly specific and affordable BTM80.  
The characteristics and biological functionality of OC, a matrix protein used for assessment of bone 
formation among many other dimensions of bone turnover, will be discussed later in this review. 
?
7.3.3 Establishing?paediatric?reference?ranges??
Variation in BTMs increases with puberty, demonstrating correlation with growth velocity in healthy 
children88,89,90 and in those with pathologically increased growth velocity91. Consequently, children and 
adolescents have elevated concentrations of BTMs due to high skeletal growth and rapid bone turnover 
compared with adults92. The highest levels of bone markers have been described in infants and children 
during the first four years of life; thereafter levels decrease slightly and remain relatively stable until 
peaking again at puberty93.  
 
The timing of puberty is crucial for final bone mass accrual as 25% increase in lumbar spine volumetric 
BMD occurs during puberty and an increase of 25% in lumbar spine volume94 is being built up during 
pubertal growth spurt. By the age of 18, a total of almost 90% of the skeletal mass is being attained95  
even if the process is individual and influenced by many physiological and pathological processes and 
factors, both in adults and in paediatric populations96,97, as listed in Text?box?4Error!?Reference?source?
not?found.. 
?
?
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Text?box?4:?Factors?influencing?bone?mass?accrual.?
 
 
Consequently, paediatric normative values are vital for differentiating between normal and abnormal 
bone turnover, investigating skeletal diseases in children or monitoring responses to bone treatment. 
Reliable assessment of paediatric reference data for BTMs requires a representative sample population 
of healthy children and adolescents within a defined geographical area. Potential geographical factors 
influencing reference values are listed in Text?box?5:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Hence, every geographical area should ideally have access to local reference values, which provide 
guidance for interpretation of the BTM results, taking into account the locally most influencing factors. 
 
 
? ?
? Genetics?and?race?
? Gender?
? Prematurity?
? Endocrine?and?mechanistic?factors?
? (Mal)nutrition?
? Pharmacological?factors?
? Vitamin?D?(in)sufficiency?(depending?on?sunlight)??
? Dietary?habits?such?as?milk?intake?
? National/regional?recommendations?for?supplementation?of?minerals?or?vitamins?
? Exercise?habits/programs?defined?by?national?school?exercise?guidelines?or?
recommendations?
? Religious?factors?such?as?veiling?
Text?box?5:?Geographical?factors?influencing?reference?values
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7.4 Glucose?homeostasis?and?bone?
7.4.1 Normal?glucose?tolerance?
The foundation of the human energy metabolism, parallel to any living organism, is related to the 
immediate need for sufficient supply of glucose to the target tissues via firmly regulated pathways. 
Glucose homeostasis in humans is regulated by a feedback loop, which includes insulin-sensitive tissues 
such as pancreatic islet cells; mostly glucagon-producing alpha and insulin-producing beta cells; liver, 
muscle and adipose tissue98. The plasma concentration of glucose is a product of the rate of the glucose 
entering the circulation balanced by the rate of glucose disposal from the circulation99. In a fasting state 
up to 80% of the glucose released into the circulation originates from the liver while kidneys are 
responsible to contribute to the remaining 20% through renal gluconeogenesis100.  
Digestion of food in the intestines converts the compacted storage carbohydrates, starch and glycogen, 
to glucose. Pancreatic ?-cells express glucose transporters, which permit rapid glucose uptake regardless 
of the extracellular glucose concentration101.   Insulin, a 33-amino acid long peptide is first synthesised 
as preproinsulin and processed to proinsulin. Thereafter, proinsulin is converted to insulin and C-peptide, 
stored in secretary granules and awaiting release via fusion of the secretory granules with plasma 
membrane on demand. Insulin is secreted primarily in response to glucose, while other nutrients such as 
free fatty acids and amino acids can augment glucose-induced insulin secretion102.?Glucose-stimulated 
basal insulin secretion, which secures the insulin necessary for basic energy needs and regulation of 
hepatic glucose production, occurs in fasting state while stimulated (prandial, bolus) insulin secretion is 
induced by increasing concentrations of glucose related to a meal or an OGTT103,104. In normoglycaemic 
individuals but also, when mimicking natural insulin secretion in insulin-insufficient individuals, 
approximately half of the total daily insulin is secreted or to be replaced as basal insulin, suppressing 
lipolysis, proteolysis, and glycogenolysis105.  
During stimulated insulin-secretion, a rapid "first phase" of insulin secretion promotes peripheral 
utilisation of the prandial nutrient load, suppresses hepatic glucose production, and limits postprandial 
glucose elevation106. First-phase insulin secretion begins within 2 minutes of nutrient ingestion and 
continues for 10 to 15 minutes. This initial secretion is followed by the second phase of prandial insulin 
secretion, continuing until a normoglycaemic state is again restored. In patients with impaired glucose 
tolerance (IGT) or in the early stages of type 2 diabetes (T2DM), first-phase insulin release is almost 
invariably lost despite the enhancement of second-phase secretion107.    
A negative relationship has been demonstrated between the principal, first phase insulin release and 
initial glucose increment after commencement of a glucose infusion108. An early surge of insulin 
secretion could potentially restrict the rise in blood glucose levels but still, the greater the insulin surge, 
the more prolonged seems the effect on glucose homeostasis. The effects of an acute first-phase insulin 
secretion has been shown to significantly affect consequent glucose tolerance by warranting more 
physiological plasma glucose levels109.  
Insulin suppresses hepatic glucose output while it stimulates the uptake of glucose, amino acids and fatty 
acids in the muscles and adipose tissue98. The amount of secreted insulin is determined by the insulin 
sensitivity, the systemic responsiveness of the tissues to insulin but also the often progressive ?-cell 
failure, or rather, a loss of ?- cell function than complete loss of ?- mass, which critically impairs the 
ability of the pancreas to respond to the glucose load 98,110. 
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7.4.2 Increasing?insulin?resistance,?hyperinsulinemia?and?progression?to?Type?2?Diabetes?
In the presence of insulin resistance, the target cells fail to respond to the insulin. Therefore, in response 
to sustained or prolonged elevated plasma glucose levels the pancreatic beta cells increase production of 
insulin in order to maintain normal glucose level98. This leads to hyperinsulinemia until the ?- cells fail 
especially to respond with the rapid first-phase insulin release and the total amount of secreted insulin 
declines. Chronic, physiological hyperinsulinemia leads to the development of non-glycogen pathway - 
dependent insulin resistance, i.e. hyperinsulinemia might not only be a compensatory response to insulin 
resistance but also become a self-perpetuating cause of the defect in insulin action111. The progressive 
decline in beta cell function and insulin action in the presence of insulin resistance gradually leads to 
hyperglycaemia and T2DM.  
Many factors such as reduced glucose utilisation by peripheral tissues (muscle and adipose tissues) 
during the absorptive state may result in increase in glucose concentration (Figure?3). Hepatic insulin 
resistance at may lead to insufficient suppression of (especially nocturnal) glucose production and output 
as well as an increase in prandial glucose excursion(s). Yet, other potential influencing factors regulating 
the hepatic glucose release, such as inadequate suppression of prandial plasma glucagon concentration, 
persistence of elevated prandial plasma free triglyceride (TG) levels, and changes in gastric emptying or 
motility due to abnormal incretin effect in addition to its role in glucose homeostasis, play a central 
role112.  
 
Figure?3:?Pathophysiological?processes?contributing?to?increased?hyperglycaemia?in?the?presence?of?
insulin?resistance.?
?
?
Adapted?from?Kahn?SE,?Cooper?ME?and?Del?Prato?S?(2014).?Pathophysiology?and?treatment?of?Type?2?Diabetes:?
perspectives?on?the?past,?present?and?future.?Lancet?383:1068?1083.?
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7.4.3 Effect?of?obesity?and?impaired?glycaemia?on?bone?homeostasis?
Obesity, impaired glucose tolerance and T2DM affect bone metabolism. Obesity, with or without 
glycaemic impairment such as T2DM, may have detrimental effects on bone metabolism through 
inflammatory cytokines, adipokines, and increased levels of free fatty acids113. However, for almost a 
century, there have been references in the medical literature indicating an increased risk of fractures 
among patients with diabetes114. This clinically relevant increased fracture risk, is not explained by lower 
BMD (when measured with DXA)115,116. In addition, detection of this elevated risk with regular 
screening of BTMs is not feasible or theoretically even possible, as no definite extrapolations can be 
made regarding the ability of BTMs to predict fractures in individuals with hyperglycaemia or diabetes, 
independent of weight117.  
Patients with T2DM have a generally increased risk of fractures although their overall BMD is not 
significantly decreased118. The rate of bone resorption and formation, as indicated by elevated bone 
turnover markers, is reduced in subjects with diabetes119. On the other hand, improved glycaemic control 
might stimulate osteoblastic differentiation and enhance bone formation. Markers of bone formation, 
such as total serum OC, have been shown to be inversely associated with glycaemic control in subjects 
with T2DM and with the presence of vertebral fractures120. Also other sources have demonstrated an 
increased OC in patients with type 1 diabetes (T1DM)119.  
?
7.4.4 Effect?of?low?birth?weight?on?glucose?and?bone?metabolism?
Increased risk of impaired glucose homeostasis, diabetes and cardiovascular disease later in life is 
associated with low birth weight121. One of the most notable studies by Hovi et al assessed the effect of 
very low birth weight (WLBW, < 1500 g) on glucose and insulin metabolism, glucose tolerance 
(measured with a 2-hour oral glucose tolerance test; OGTT) and insulin sensitivity (by homeostasis 
model for insulin resistance, HOMA-IR), serum lipid levels and blood pressure in young adults born with 
WLBW122. This study observed significant differences in markers of glucose homeostasis between the 
VLBW and control subjects; the VLBW subjects having a 6.7% higher glucose levels, 16.7% higher 
fasting plasma glucose (FPG) and 40% higher 2-hour insulin concentration after an OGTT. None of the 
subjects had T2DM but some subjects in both groups had impaired glucose tolerance (IGT). 
Hyperinsulinemia as a sign of increased insulin resistance and clinically confirmed IGT are generally 
acknowledged early indicators of impaired regulation of glucose metabolism and reduced peripheral 
insulin sensitivity98. 
In the same cohort, there were also significant differences in BMD between the VLBW subjects and the 
controls: the VLBW subjects had a significantly lower lumbar spine (LS), femoral neck (FN) and whole 
body BMD123. The differences in Z scores were up to 0.51 units in the LS and 0.56 in the FN and the 
differences could only partially be explained by smaller body size or lower exercise intensity. The 
observed difference remained significant and clinically relevant even after adjustment for several 
potential confounding factors. 
Individuals with VLBW are also known to be predisposed to short final height124 and as young adults 
have reduced BMD125. This might be due to their smaller size even if the measurements have been 
adjusted for bone size (by estimation of volumetric bone density)125. The association between these 
clinical characteristics and the impact of VLBW on glucose metabolism and other cardio-metabolic 
outcomes such as lipid profiles, blood pressure, renal function, urinary albumin, and thyroid function 
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were investigated in 111 Japanese young adults with VLBW126. A total of 36% of the subjects had short 
stature with a final height  below the 10th percentile, 7.2% had IGT or T2DM. Short stature strongly 
correlated with glucose intolerance (OR 11.1; 95% CI 1.92, 99.7; p?=?0.006) and the final height was 
inversely associated with markers of insulin resistance/glucose sensitivity and total/LDL-cholesterol. 
The associations of final height with insulin sensitivity and lipid profiles remained after adjustment for 
target height and age at the onset of puberty. The authors concluded that shorter final height was 
associated with less favourable metabolic profiles in young adults with VLBW, and may be partly 
mediated by reduced insulin sensitivity. These associations were independent of target height or age at 
puberty onset. 
A limited number of studies have evaluated the markers of bone metabolism in VLBW subjects. Some 
studies have reported increased OC in subjects born with VLBW127 while in another study (which did 
not assess OC) no differences in formation or resorption markers were observed125. 
?
?
7.5 The?suggested?link?between?osteocalcin?and?energy?metabolism?
In general, metabolic diseases are known to influence bone homeostasis128. Leptin, an adipocyte-derived 
hormone, has been previously shown to inhibit bone formation by acting on osteoblasts via central neural 
pathways128,129. However, based on several recent, experimental evidence130,132, OC is believed to play 
a central role in regulating the cross talk between murine fuel and bone metabolism128,129,130,132. These 
studies have suggested another neuroendocrine circuit linking bone and glucose metabolism and fat mass. 
These new data imply existence of bi-directional signalling between bone and metabolic /energy 
homeostasis; OC indicated as a key mediator of this signalling. OC, which exhibits several hormonal 
characteristics131, has been indicated to regulate glucose metabolism and fat mass in mice132. Yet, its 
specific function remains indistinct.  
?
7.5.1 Osteocalcin?
OC in an osteoblast lineage-derived, Vitamin K-dependent secreted protein, a macromolecule, which is 
implicated in bone mineralisation as it forms 1-2% of the bone matrix131 and also in calcium homeostasis. 
OC exists in the general circulation in fully carboxylated, partially carboxylated and completely 
uncarboxylated forms but the biological function of these different forms is still not properly mapped. ?
As OC is being specifically expressed by osteoblasts, most of the historical studies have focused on the 
characterization of OC as a predictor of fractures and solely as a component of bone metabolism. Already 
in early 1990’s serum OC was establish to be a marker of both high bone formation but also high bone 
turnover133. OC has also been shown to correlate with serum testosterone and bone maturation in boys134.  
Previous studies in paediatric populations have demonstrated that serum OC concentration is a sensitive 
biochemical marker of skeletal development and growth also with changing weight/obesity status135. 
Only recently, the role of osteocalcin as an endocrine factor exerting a significant control on energy 
metabolism has been suggested.  
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Serum?osteocalcin?
Serum OC is one of the very few osteoblast-specific molecules, synthesised in the bone matrix and it has 
been shown to exhibit several hormonal characteristics; it is a cell-specific molecule, synthesized as a 
pre-pro-molecule and it is secreted into general circulation131. OC undergoes an unusual post-
translational modification whereby glutamic acid residues are carboxylated to form ?-carboxyglutamic 
acid (GLA) residues131. This process is Vitamin K dependent136. The degree of their carboxylation 
defines the affinity of the molecule to the skeleton as the formation of GLA residues enables OC and 
other ? –carboxylated proteins to bind to calcium.  
OC’s biological function might be related to its structure with GLA residues as OC has been suggested 
to affect the growth or maturation of the mineral phase, composed by crystalline HAP137. This is 
supported by its first appearance coinciding with the onset of mineralisation in utero138. OC levels are 
also increased in parallel with HAP deposition during skeletal growth and mineral maturation139.  
In mice approximately 10% of the circulating OC present as undercarboxylated OC while in humans it 
accounts up to 40%140,141. Some studies have though shown that in elderly individuals up to 91% of the 
total OC is carboxylated142. Whereas carboxylated OC (cOC) has a higher affinity for HAP than 
under/uncarboxylated OC (unOC)143, the biological role of ?-carboxylation remains partially unclear. For 
decades, the biological role of OC has been a target of various attempts to identify its role, even during 
foetal developmental stage. There are limited studies to report the presence of OC in amniotic fluid. 
Mimouni et al reported as early as in 1987 from 15 to 43 weeks of gestation (n=131) the presence of OC, 
which had the same gel-filtration characteristics as serum OC144. In 67% of the samples OC could not be 
detected, mostly potentially due to their historical RIA method having had an insufficient detection limit 
(0.1 ng/ml). A total of 95% of the samples had a concentration below 2.4 ng/ml and the authors defined 
that as a limit for normal levels of OC in amniotic fluid. None of the pregnancies studied lead to birth of 
a child with a mineral bone disease, and no reports of any metabolic abnormalities were available or 
studied.  
Based on the recent knowledge, advanced technology and development in understanding the role of OC 
in regulation of energy metabolism, the mapping of OC expression during foetal but also later 
development might provide us with greater understanding of the biological roles of carboxylated and 
uncarboxylated forms of OC.  
?
Under/uncarboxylated?osteocalcin??
A small but detectable and measurable amount of unOC (or Glu-OC; indicating the lack of carboxylation 
of the glutamic residue) can be detected in the serum145. Its presence might indicate that either some OC 
is being secreted in an incomplete form by the osteoblasts or that OC is enzymatically or otherwise being 
decarboxylated outside the cells. Only limited number of, mostly non-validated assays, are available for 
appropriate detection of un OC concentrations and thus most of the studies have estimated the proportion 
of unOC by simply deducting the amount of cOC from the total OC. Nevertheless, this is not optimal as 
serum unOC is highly correlated with total OC while the percentage of unOC (%unOC) is not146. A few 
commercially available assays for unOC may overestimate the real OC concentration as the antibody 
used in the assay recognises the N-terminal fragments of OC147 (especially if intact), instead of total OC 
concentrations being appropriately explored.  
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Urinary?osteocalcin??
OC is metabolised in urine as measurable mid-molecule fragments (U-midOC). The urinary levels of OC 
correlate with serum OC concentrations and other serum BTMs in adults148. U-midOC molecular 
fragments, which accumulate in urine, have been used alone in adults as an index of bone turnover, but 
it not yet been established as a marker of bone turnover in children and adolescents while there are several 
studies evaluating serum OC in children and adolescence149,150,151. One study assessed the urinary mid-
fragments predicted the catch up growth in prematurely born infants152. 
 
7.5.2 Preclinical?evidence?–?the?foundation?of?the?hypothesis?
The group of Gerard Karsenty put forward a paradigm-shifting hypothesis (Figure?4) according to which 
bone contributes in, and even regulates the whole-body physiology, energy metabolism and even 
fertility153. These series of theories were initiated based on findings by Lee et al who showed that mice 
lacking the OC encoding gene (OC -/-) have an abnormal amount of visceral fat, and present with signs 
of glucose intolerance, insulin resistance and impaired insulin secretion compared to wild-type (wt) 
mice132. On the other hand, administration of recombinant OC in such mice significantly improved 
glycaemia and increased insulin secretion130. Simultaneously, presence of an osteotesticular protein 
tyrosine phosphatase, OST-PTP, a factor regulating insulin sensitivity via dephosphorylation of the insulin 
receptor in osteoblasts, was observed in this mouse model. OST-PT is only expressed in osteoblasts and 
Leydig cells while now claimed to be universally involved in the regulation of carboxylation of OC and 
its metabolic effects– a claim slightly hampered by the fact that no corresponding analogous molecule 
could be found in humans. However, another model was suggested to be responsible for the origin of the 
uncarboxylated form of OC, excluding the previously well-established role of vitamin K in the 
carboxylation of OC: insulin signaling in osteoblasts. According to this hypothesis, insulin signalling 
induces a decrease in the expression of OPG, which in turn activates bone resorption and therefore this 
potentially spontaneous decarboxylation of OC in an acidic environment would promote the effect of 
unOC on glucose and insulin154,155. Hence, Lee et al had for many researchers demonstrated that unOC 
regulates glucose homeostasis as in their model unOC was alone able to induce expression of adiponectin, 
insulin and markers of pancreatic islet cell proliferation132.  
In these ex-vivo studies by Lee et al, insulin secretion was stimulated when isolated pancreatic beta islets 
from wt mice were co-cultured with wt osteoblasts or in the presence of supernatants from cultured 
osteoblasts132. This hypothesis suggested the presence of an osteoblast-derived circulating factor, which is 
capable of regulating pancreatic ?-cells or even the islet cell function as an entity. In similar co-culture 
assay of wt osteoblasts with adipocytes, the group demonstrated also an increase in adiponectin expression 
and action132. As per their results, OC and leptin may thus, at least in rodents, contribute to the components 
of the dysmetabolic phenotype. Increased adiposity, insulin resistance and low bone formation and 
reduced numbers of osteoblasts were observed also by others studying mice lacking insulin receptors in 
their osteoblasts but the effect of infused unOC in these mice resulted nevertheless in a modest 
physiological effect in insulin- and glucose tolerance tests155,156. 
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Figure?4:?The?hypothesis?or?speculative?model?of?the?role?of?osteocalcin?on?energy?metabolism?via?
resorption?induced? activation?of?decarboxylated?OC,?unOC,? and? its? effect?on? key? components?of?
glucose?homeostasis.?
 
 
Adapted from Ferron M et al. Insulin signalling in osteoblasts integrates bone remodeling and energy metabolism. Cell (2010) 
142, 296-308 and Karsenty G & Ferron M. The contribution of bone to whole-organism physiology. Nature (2012) 481: 314-
320. FoxO1; Forkhead O1 protein which regulates metabolic homeaostasis in response to oxidative stress; Esp, a pseudogene 
encoding OST-PTP in rodents; Glu-OC and, Gla-OC; different degrees of carboxylation of OC indicating active and inactive 
forms of OC, respectively.  
 
 
The effect of these moderate changes in osteoblastic insulin signaling on glucose tolerance was explored 
in yet another mouse model, which either over- or under- expressed the insulin receptor157. No changes 
were observed in glucose metabolism (vs. wt) when the animals received a normal diet. Yet, when the 
animals were fed a high-fat diet, insulin resistance was declining in those over-expressing, or exacerbated 
in those under-expressing the insulin receptor (vs. wt animals on the same high-fat diet)157. 
Simultaneously, parameters exploring the impact of this modification on bone turnover were lower in 
animals on the high-fat diet with relatively larger reduction in those under-expressing the insulin receptor. 
Circulating levels of both total OC and unOC decreased in parallel with reduced bone turnover, which 
was also confirmed by reduction in other BTMs such as CTX and PINP. The researchers gave also daily 
injections of unOC to all mice, after which glucose tolerance and insulin sensitivity were being 
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improved157. Inconsistently, total OC increased three times that of unOC, suggesting some conflicts or 
irregularities in their analytical methodology. 
On the other hand, the endocrine function of adipose tissue is well characterised132,158 and studies to 
establish how adipose tissue and adipocyte-derived endocrine-acting factors affect the skeleton are 
ongoing. Based on the above-mentioned cell assay and rodent studies, insulin signalling and increased 
rate of resorption may lead to increase in OC secretion in osteoblasts154, which in turn increases insulin 
sensitivity159 and increase pancreatic insulin production160. These preliminary pre-clinical data indicated 
that the bi-directional regulatory role of the skeleton on glucose and energy homeostasis appears to be 
mediated by OC132 but there are only limited clinical data available to confirm this in patients with impaired 
glucose metabolism or impediments in their metabolic pathways.  
One of the key questions thereby is whether bone regulates such physiological functions, which at least 
primarily seem to have no obvious connection with bone health per se. Most hormones exert several 
functions so why not also OC. According to another exhilarating theory, unOC was also claimed to play 
a role in male fertility via increased testosterone production in male mice161,162. As described above, OST-
PTP was identified in testosterone producing Leydig cells and the hormone production was significantly 
diminished when co-cultured with primary osteoblasts lacking the OC gene161,162. Additionally, OC was 
reported by some, but not confirmed by others, to be a G protein-coupled receptor family C group member 
6 member A (GPRC6A) agonist, a receptor on Leydig cells157,162,163,164. Nevertheless, although a total OC 
decreased during use of anti-resorptive medications in human male subjects, no change in circulating 
testosterone concentrations has been observed165. Therefore, the relationship between OC and testosterone 
may also be reflective of the well-established hormonal relationship between bone and testosterone, 
related to the role of testosterone in bone formation and resorption166.  
 
7.5.3 Clinical?evidence?
There is a wealth of pre-clinical evidence referring to individual findings supporting or mirroring the 
suggested evidence regarding the bi-directional regulatory pathway after the first conceptual analysis by 
the group of Karsenty were presented. Yet, the clinical evidence is scant and there are no prospective, 
pivotal clinical studies, which would have addressed this hypothesis.  
?
Post?hoc?analyses?in?patients?with?osteoporosis?
Pittas et al were among the first to test and report an inverse association between total serum OC and the 
markers of metabolic dysfunction (fasting hyperglycaemia, insulin resistance and systemic inflammation) 
and measures of adiposity (body mass index; BMI and body fat) in a cohort of humans, in this case elderly 
subjects167. In this post hoc analysis, 5% of the studied patients had T2DM, 29% IGT and 66% normal 
FPG. The patients in the highest OC tertile had statistically significantly lower rise in FPG vs. the lower 
tertiles167. Another early report from the Swedish cohort of osteoporotic men (MrOS; a cross-sectional 
association study in osteoporotic males), indicated that total plasma OC was inversely associated with 
BMI, fat mass and plasma glucose while it was not significantly associated with height or lean mass168. 
Plasma OC explained 6.3 % and 2.5 % of the variance in plasma glucose levels in all subjects and those 
without diabetes, respectively. However, this study evaluated again only the total OC levels and not 
specifically unOC, which had been shown to exert the effects at least in animal studies132. Some smaller 
studies have reported similar post hoc findings169,170,171.  
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Cohorts?with?metabolic?syndrome?or?dysglycaemia?
In the subjects with diabetes of the MrOS cohort168, plasma (total) OC was negatively associated with 
total fat and trunk fat demonstrating that plasma OC is specifically associated with fat mass but not with 
lean mass. The negative association between OC and plasma glucose levels was strong while that between 
plasma OC and serum insulin was not as obvious in both all subjects and those without diabetes. 
Evaluation of serum lipids demonstrated that serum TG and HDL-cholesterol, but not total cholesterol or 
LDL-cholesterol, were moderately associated with plasma OC in all groups. In a smaller subgroup of 
subjects with diabetes (n=153) there was a similar trend of an association between OC and plasma glucose 
as seen for the larger subgroup of normoglycaemic subjects (n=857) but this trend did not reach statistical 
significance. No significant interaction between OC and diabetes (Yes/No) was observed for the 
association with variables relating to glucose homeostasis (FPG, HOMA index) or the different parameters 
reflecting body fat (total body fat, trunk fat and percent body fat, fat%). Thus, according to the authors, 
OC was clearly inversely associated with parameters reflecting fat mass and plasma glucose. According 
to this study, OC is an independent negative predictor of FPG and it is not mediated by insulin levels nor 
caused by T2DM or its treatments.  
Additionally some smaller studies have reported similar findings and added novel observations for the 
effect of OC on lipids. Zhou et al who studied Chinese diabetes patients reported serum TG levels as an 
independent factor influencing OC in pre-menopausal women whereas age, fat%, HDL cholesterol, FPG 
and fasting serum insulin were independently correlated with OC in men169.  
 
Table?1 summarises the key clinical evidence indicating a relationship or association between OC (total, 
carboxylated or uncarboxylated) and markers of metabolic syndrome/disturbances, insulin resistance or 
other surrogate markers of energy metabolism. Most of the evidence comes from cross-sectional post hoc 
analyses of cohorts targeting other primary endpoints and thus these analyses preclude direct inferences 
concerning causality or a temporal relationship in a genuine longitudinal setting. Similarly, the indicated 
(mostly inverse) associations between total OC and the markers of metabolic impediments are modest, 
and the included cohorts recruited mostly individuals with subsequent confounding co-morbidities. In 
these analyses, the degree of OC carboxylation was seldom or reliably taken into account as 
uncarboxylated form of OC is not widely available or measured. Therefore, most of them incorrectly 
assume that total and uncarboxylated forms of OC have the same molecular-physiological role, thus 
introducing an unintentional bias in the literature used to support the model by Karsenty et al. The 
discrepancy among these studies may additionally be due to diversity within the evaluated clinical cohorts 
and the methods used to assess OC, but it could also be indicative of the age-dependency of the effect of 
OC on glucose metabolism among many other potential factors.  
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8. The?aims?of?the?research?
 
Despite the growing body of evidence for the role of bone-derived OC in energy homeostasis there are 
yet no studies which would have evaluated a) how rapidly OC responses to changes in glucose 
homeostasis, b) whether these changes are biologically substantial and clinically relevant in 
normoglycaemic adults and c) how these changes associate with skeletal parameters.  
Therefore, the specific aims of this research have been as follows:?
1. to explore acute glucose-induced changes in bone metabolism and bone turnover markers in a 
cohort of young adults (I: ‘Pilot’) 
2. to explore the association between bone and glucose metabolism during a standard OGTT in 
healthy young adults born with VLBW vs. those born at term (II:’VLBW cohort’)
3. to compare multiple bone turnover markers between obese subjects with childhood-onset obesity 
and age- and sex-matched normal-weight controls and also, to evaluate the response of BTMs, 
including OC, to a rapid increase in circulating glucose levels, and the interplay between glucose, 
insulin and BTMs, during an OGTT (III: ‘ELLU’) 
4. to establish sex- and age-specific BTM reference intervals in healthy Finnish children and 
adolescents and to assess the variation by anthropometric variables, pubertal status and body 
composition on BTMs, especially on urinary, serum total and carboxylated OC levels (IV: 
‘normal reference range cohort’) 
 
? ?
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9. Materials?and?methods?
9.1 Ethical?considerations??
All the studies were conducted in accordance with Declaration of Helsinki and the study protocols were 
approved by the Research Ethics Board of Helsinki University Central Hospital and/or Uusimaa Hospital 
District (HUS). The individual approval numbers are as follows: Study III (Dno 183/13/03/03/2010) and 
Study IV (HUS/212/E7//2005). Details for Study I and II can be retrieved from Petter Hovi et al. 
All adult subjects provided a written informed consent (Studies I, II and III) while for all the paediatric 
subjects (in study III when applicable, and study IV) the consent was obtained from the parents and an 
assent from the children and adolescents. No additional invasive measurements beyond regular blood 
and urine sampling were imposed. The exposure to radiation during assessment of body and bone 
composition with dual X -ray was limited to the minimum. All subjects were informed about any 
clinically significant findings and referred to appropriate further medical care, if applicable.  
 
9.2 Subjects?and?study?designs?
Study I was a pilot study (‘Pilot’), which included the 23 sequentially first, more intensively studied, 
subjects enrolled in the VLBW cohort recruited through data from the Population Register Centre of 
Finland as explained below. This cohort, 12 females and 11 males, was pooled to represent a group of 
young adults close to the time of peak bone mass attainment to demonstrate the effect of acute glucose 
load on bone diverse turnover markers, independent of their past as infants with VLBW or their peers. 
Study II/VLBW cohort consisted of 338 subjects, enrolled by Hovi et al to participate in an assessment 
of the various consequences of VLBW status later in life; premature VLBW subjects (n=166) and 
subjects born at term with normal birth weight (n=172)122. All subjects with available, consecutive serum 
samples at baseline and 2 hours during OGTT were included in the assessment of OC and metabolic 
parameters in this study.  
 
? Study I/Pilot and Study II/ VLBW cohort: The original study cohort as collected by Hovi et 
al122 comprised 335 consecutive, prematurely born (gestational age, GA < 37 weeks) VLBW 
infants born between January 1978 and December 1985. These subjects represented those 
discharged alive from the neonatal intensive care unit of Children’s Hospital at Helsinki 
University Central Hospital, Finland. A comparison group was selected from the records of all 
consecutive births at each birth hospital among the following infants; the next available singleton 
born at term (GA ?37 weeks) of the same sex and who was not small for GA (SD score for birth 
weight ??2.0). All the subjects were traced in 2004, in their young adulthood through data from 
the Population Register Centre of Finland. Mortality from hospital discharge to June 2004 was 
generally low, 1.8% for the VLBW subjects and 1.0% for the comparison group born at term. 
Birth weight ranged from 600 to 1500 g in the VLBW group and from 2560 to 4930 g in the term 
group; GA ranged from 24.0 to 35.6 weeks in the VLBW group and from 37.0 to 42.9 weeks in 
the term group. Among the survivors, 95.1% of VLBW subjects and 96.8% of subjects born at 
term were identified and a total of 255 VLBW subjects and 314 subjects born at term who were 
living in the greater Helsinki area were invited to participate in the study. A total of 338 subjects 
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agreed to participate; 166 of the VLBW subjects (65.1%) and 172 of the subjects born at term 
(54.8%). Subjects with T1DM (n=1), concomitant or chronic systemic glucocorticoid use (n=1), 
pregnancy (n=2) or insufficient fasting prior to OGTT (n=2) were excluded from the analyses.  
Study III/ELLU (ELLU- Elintavat ja luusto nuorilla, i.e. in Finnish for Lifestyle and skeleton in young 
subjects) cohort assessed the skeletal and metabolic characteristics in 42 eligible subjects with severe 
childhood obesity, necessitating specialist care.  
 
? Recruitment of subjects into ELLU started in 2011 and the main inclusion criteria for the 
enrolment of the targeted obese subjects included weight-for-height ratio exceeding 60% before 
7 years of age (according to local, Finnish growth standards) and a referral due to severe 
childhood obesity to Children’s Hospital, Helsinki University Central Hospital. The Subjects 
must have lived at the age of 7 years within the capital region of Helsinki and they were to be 
between 15 and 25 years of age at the time of inclusion in ELLU. In all, out of 230 eligible 
subjects who were invited to participate in the study, 42 (18%) subjects consented. All 
participating subjects had been followed by a paediatrician at the Children’s Hospital and 
common endocrine and/or genetic causes of obesity had been excluded (e.g. Prader Willi 
syndrome, pseudohypoparathyroidism, hypercortisolism, hypothyroidism). Before first study 
visit two obese subjects withdrew their consent due lack of time, one due to pregnancy, and one 
due to diagnosis of T2DM. Additionally, OGTT was incomplete in three obese subjects. For each 
subject an age- and sex matched control was selected from the civil register, limited to the capital 
region of Helsinki. Exclusion criteria for the control subjects were obesity before age of 10 years 
(weight-for-height ratio above 40%). Altogether 35 controls provided a consent. However, in one 
subject OGTT was incomplete and thus a total of 34 age- and sex matched patient-control pairs, 
who had complete data, were included. 
Study IV/ Normal reference range cohort was initiated in 2005 for cross-sectional, school-based 
assessment of the impact of exercise, nutrition and hereditary factors on bone health and/or related 
parameters in healthy children and adolescents (age between 7 and 19 years) in Helsinki region. For 
evaluation of serum OC, the final eligible cohort with sufficient sampling material consisted of 172 
subjects.  
 
? The original study comprised 195 children and adolescents who were recruited from randomly 
selected school classes in one primary and one secondary school in order to cover all age 
groups176. The aim was to reach a higher than a 60% participation rate. Participation in this study 
was voluntary and invitation letters were given by the teachers to the pupils and their parents. All 
those willing to participate were included. Our sub-analysis included a total of 172 subjects from 
the original cohort, 106 girls and 66 boys, who presented with normal bone mineral density 
(lumbar spine Z score between -2 and +2) and had retrievable data for clinical characteristics, 
including puberty stage, serum and urinary samples, and DXA parameters including whole body 
fat%. One outlier (a boy) was removed due to unreliable test result for an exceptionally high 
urinary OC value beyond reliable detection limit despite having met all the inclusion criteria.  No 
additional exclusion criteria were introduced. 
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Table?2:?Summary?of?the?study?cohorts?and?key?analysis?methods?
a) Serum ?-CTX, P1NP and TRACP5b,  
b) BAP 
c) Serum P1NP and serum ICTP, U-NTX, ALP 
 
 
9.3 Methods?
9.3.1 Assessment?of?clinical?characteristics?(I?IV)?
All subjects in Study I-III were evaluated for anthropometry (weight, height, waist and hip 
circumferences, BMI). In Study I/II the subjects completed questionnaires mapping their past medical 
history, their regular leisure-time activity and exercise. In addition, details regarding the educational level 
of their parents or caregivers were recorded and the parent’s history of diagnosed T1DM or T2DM. The 
blood pressure measurements were standardised and performed by measuring from the right arm of each 
subject. In Study III questionnaires were used to collect information regarding smoking, fractures and 
physical activity additional to recent history during the last 12 months focusing on commuting for school 
or work, guided or non-structured free time activity.  
In Study IV targeting the paediatric population, information on medical and fracture history, medications, 
overall health, age at menarche, use of vitamin D and calcium supplements, and data about physical 
activity and dietary intakes were collected with a questionnaire. Height (cm), its SD and weight (kg) plus 
relative body weight (weight %) were measured and compared with Finnish growth charts177. No analysis 
Study 
cohort 
Sample 
size (n) Main inclusion criteria 
Serum (S) / 
urinary (U) 
OC analysis 
Other 
BTMs OGTT 
Bone / body 
composition 
analysis 
I / Pilot 23 Healthy young adults x (S) x(a x x 
II / VLBW 337 
Young adults born with 
VLBW or at term x(S) - x x 
III / ELLU 34 
Adolescents and young 
adults with childhood -
obesity 
x (S) x(a,(b x x 
IV / 
Normal 
reference
range
172 
Healthy children and 
adolescents x (S,U) x
(c - x 
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on ethnicity due to limited ethnic heterogeneity in this cohort was included on results presented for this 
research (as subjects were mostly Caucasians). 
Based on serum gonadotropin and sex steroid concentrations, pubertal development was scored either as 
pre-, mid-, or post-pubertal by a paediatric endocrinologist. A united scale was introduced by converting 
the available Tanner stages into pre-, mid-, or post pubertal categories as follows: Tanner stages I–II 
were considered as pre-pubertal, stages III and IV mid-pubertal and stage V as post-pubertal. 
The subjects were evaluated for clinical characteristics, medical history (including their parents’ history 
of T1DM and T2DM) and for markers of adiposity and glucose metabolism. 
?
9.3.2 Biochemistry?
In all studies (I-IV) blood (serum /plasma) samples and second void urine were collected at 8–10 am 
after an overnight fast. Serum 25-hydroxyvitamin D (25-OHD) was assayed with high-performance 
liquid chromatography (HPLC, evaluated by Vitamin D External Quality Assessment Scheme, DEQAS), 
and plasma fasting parathyroid hormone (PTH) by an immunoluminometric method. 25-OHD, PTH and 
other biochemistry samples such as electrolytes, including (ion) calcium and potassium, were analysed 
as per validated standard protocols at HUSLAB. 
 
Oral?glucose?tolerance?test?(I??III)?
All subjects attended the clinic after an overnight fast of at least 10 hours. A 2-hour OGTT (75 g glucose) 
was initiated between 6:00 am and 11:15 am in Study I-III, depending on the schedule of the subjects. 
They ingested 75 g glucose solution, preferably within 5 minutes, after which plasma and serum samples 
were collected from a cannula inserted in an antecubital vein at baseline (0 min) and at 120 min in Study 
I and II, additionally at 30, 60 and 90 minutes in Study III.  
Plasma glucose concentrations were measured by spectrophotometric hexokinase and glucose-6-
phosphate dehydrogenase assay (Gluko-quant glucose/hexokinase, Roche Diagnostics) with a Hitachi 
Modular automatic analyzer at HUSLAB. At glucose concentration of 4.7 mmol per liter (84.7 mg per 
deciliter), the inter-assay coefficient of variation is 2.3%178. Impaired glucose tolerance was defined 
according to WHO as plasma glucose concentration ?6.1 but <7.0 mmol/l at 0 min (fasting) and/or ?7.8 
mmol/l but <11.1 mmol/l at 120 min. Diabetes was defined by using standard criteria from international 
guidelines179 as plasma glucose concentration ?7.0 mmol/l at 0 min (fasting) and/or ?11.1 mmol/l at 120 
min. Serum samples were stored at -70 ?C or colder until further analyses. 
Based on OGTT findings, all subjects in study I and II were considered normoglycaemic at baseline 
(mean fasting plasma glucose ± SE 4.44 mmol/L ± 0.09 and mean fasting serum insulin 6.5 mU/l ± 0.60) 
and none had diabetes based on OGTT results. One subject in Study I with normal baseline glucose and 
insulin values had an increased glucose value at 120 min (9.2 mmol/l) and insulin value (288.0 mU/l) 
indicating signs of impaired glucose tolerance and driving the mean values for these parameters in the 
Study I cohort. At repeated testing both the 120 min both the glucose and insulin values were within 
normal.  
In Study III population, 55% of the obese subjects and 3% of their controls had elevated fasting serum 
insulin concentrations (>12 mU/l) indicating increased insulin resistance or signs of pre-diabetic 
hyperinsulinemia. None of these subjects had a confirmed T2DM based on other glycaemic parameters.?
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Adiponectin?(II?III)?and?leptin?(III)?
Adiponectin was assessed as an exploratory parameter for the subjects in Study II (unpublished data) and 
Study III. Serum adiponectin was determined with Human Total Adiponectin/Acrp30 Quantikine ELISA 
Kit and serum leptin with Human Leptin R Quantikine ELISA Kit (R&D Systems, Minneapolis, USA) 
with intra- and inter- assay CV of < 12%.  
 
Measurement?of?insulin,?HOMA?IR?and?HbA1c?(II,?III)?
Serum insulin was measured with time-resolved immunofluorometric assay (Perkin Elmer Life Sciences, 
Finland) with a detection limit of 0.5 mU per liter (3 pmol per liter) and an inter-assay coefficient of 
variation of less than 4%180. The insulin-resistance index determined by homeostasis model assessment 
(HOMA-IR) was calculated as the product of the fasting serum insulin concentration (in milliunits per 
litre) and fasting plasma glucose concentration (in millimoles per liter) divided by 22.5181. The 
glycosylated haemoglobin (HbA1c) was measured by direct photometric immunoassay from serum (in 
%, normal range 4-6%) at HUSLAB according to standard protocols.  
 
9.3.3 Bone?turnover?markers?(I?IV)?
Serum?osteocalcin?(I?IV)?
Serum total OC and cOC were determined at 0 min and 120 min in an OGTT by previously described 
two-site immunoassay protocols with monoclonal antibodies (Mab)182. Two Mab-Mab combinations 
were selected on the basis of previous, validated assays and modified by the undersigned based on test 
calibration runs in order to reduce the background signal. The two-site immunoassay for serum total OC 
is based on Mabs 2H9 and 6F9 and detects the large N-terminal mid-segment of the OC molecule. Assay 
for cOC utilised the Mabs 6F9 and 3H8, which detect the same fragments but prefer ?-carboxyglutamic 
acid (Gla) containing forms of OC, with <10% cross-reactivity to completely undercarboxylated OC (i.e. 
unOC)183. The Mabs were raised either against bovine OC (3H8) or a fusion protein consisting of 
glutathione-S-transferase or human OC (6F9 and 2H9). The Mabs were prepared and provided for these 
analyses by the University of Turku, Institute of Biomedicine. 
In the assay, 200 ng of biotinylated capture Mab and 100 ng of europium-labelled tracer Mab per well 
were used. Synthetic peptide of human OC amino acids 1-49 (Advanced Chemtech, USA) was used as a 
calibrator. Streptavidin-coated microtiter plates were from Kaivogen (Turku, Finland) and other 
immunoassay reagents (Delfia® Assay Buffer, Wash Solution and Enhacement solution) from Perkin 
Elmer Life Sciences (Turku, Finland). Time-resolved fluorescence was measured with Victor2 
Multilabel Counter (PerkinElmer Life Sciences). All samples were measured as duplicates and 
simultaneously at the end of each study. In order to reduce the bias by inter-assay variability, samples 
for each subject (0 min and 120 min) were analysed in parallel. The intra- and inter-assay variations were 
4.4% and 9.0%, for total OC and 2.5% and 8.0% for cOC, respectively.  
In study II with VLBW cohort, due to lack of validated method for accurate analysis of unOC values, we 
used a calculated value for uncarboxylated OC, which was derived from total OC and cOC values (unOC 
= total OC minus cOC).  
?
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Figure?5:?The?principle?of?two?site?osteocalcin?immunoassays?
?
SA;?Streptavidin?–coated?wells?on?a?microtiter?plate,?Bio;?biotinylated?Mab,?OC;?osteocalcin?from?sample?or?
standard,?Eu;?europium?labeled?Mab?
?
Urinary?osteocalcin?(IV)?
Urinary osteocalcin was determined with a two-site assay for osteocalcin mid-fragment (U-MidOC), 
which is based on the same Mab –binding principle as the serum assays for OC. The samples were 
collected as the first morning void and the results were normalized for urinary creatinine determined with 
the alkaline picrate reaction and expressed as ratios. The calibration series covered the range from 0.3 to 
90 ?g/L and any samples beyond the upper limit were considered unreliable. The within-assay (CVa) 
and between-assay (CVi) variations for the assays were 1.7 and <12% for U-MidOC. All analyses were 
performed blinded and in duplicates. The samples for each time point were analysed simultaneously to 
minimise inter-assay variability. 
?
Other?bone?turnover?markers?(I,?III,?IV)?
 
In Study I and III bone resorption was assessed by measuring serum levels of ?CTX-I and TRACP5b 
using commercial, automated Serum CrossLaps® ELISA and BoneTRAP® Assay, respectively (both 
using IDS Ltd, UK). Bone formation was assessed by measuring serum intact P1NP using automated 
analyser IDS-iSYS Intact P1NP assay (IDS Ltd, UK). Samples were analysed blinded and as duplicates, 
except for P1NP which was analysed using single sample due to insufficient sample volume for duplicate 
testing. According to the manufacturer, intra- and inter-assay variations for the assays are for ?CTX-I 
<6% and <10%, for TRACP5b <6% and <6% and for P1NP <4% and <6%, respectively. The BTM 
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measurements in Study I were performed by Pharmatest (Oulu, Finland) and in Study III by ValiRx 
Finland Ltd (Oulu, Finland).  
 
In Study IV Serum intact N-terminal propeptides of type I collagen (S-P1NP), Serum Type I collagen 
carboxyterminal telopeptide (S-ICTP) and alkaline phosphatase (ALP) were determined per validated 
standard protocols of the Central Laboratory of Helsinki University Central Hospital as described 
elsewhere 184.?Concentration of type I collagen crosslinked N-telopeptide (INTP or NTx) was measured 
from second void urine samples with Osteomark® NTx Urine Enzyme-linked Immunosorbent Assay 
(Alere Scarborough, Inc., Scarborough, USA) with intra- and inter-assay CV% < 8. The given values 
(nM Bone Collagen Equivalents) were corrected with urinary creatinine concentration (nM). 
?
9.3.4 Bone?and?body?composition?analysis?(II,?III,?IV)?
In Study II, bone mineral content (BMC) and areal BMD (aBMD) for the lumbar spine (L1–L4) were 
measured with dual-energy X-ray absorptiometry (DXA, Hologic Discovery A, software version 12.3:3) 
and transformed into age-adjusted Z scores using the equipment-, age-, and sex-specific reference data. 
A cut-off Z score value of -1.0 was chosen to define reduced BMD.  Body composition, including lean 
body mass and fat percent (fat-%), was determined with the same DXA equipment. 
A total of 284 subjects (of 332) were available for the analysis of lumbar spine aBMD, which was chosen 
as the site for analysis due to its high content of trabecular bone and active turnover. The reasons for the 
missing BMD results included unwillingness to undergo DXA, pregnancy, cerebral palsy, several 
compressed lumbar vertebrae or foreign objects in the scanning area. Scans with foreign objects such as 
surgical fixation material or jewellery in the measurement area (five subjects) were omitted from the 
analysis. If more than one lumbar vertebra was compressed, the corresponding lumbar spine scan was 
excluded from the analysis (two subjects); if only one lumbar vertebra was compressed, BMD without 
the affected vertebra was used (seven subjects).  
In Study III, whole body bone area (WB BA) was measured with Lunar Prodigy Advance DXA. 
Calibration was performed with a spine phantom; inter-CV% for BA was 0.38%. Reducibility of DXA 
measurement for total body is: BMD= 0.63%, BMC= 0.45% and BA= 0.78%185. Four obese subjects 
exceeded the maximum weight for the DXA device (160 kg) and therefore the mean WB BA value for 
all obese subjects (2570 cm2) was used for them in the multivariate data analyses. 
In Study IV, BMD, BMC and WB BA, were measured with DXA; Hologic Discovery A, paediatric 
software, version 12.4, from the LS (L1-L4), total hip and WB. DXA measurements were performed 
within three months of the biochemical sampling. All measured values were transformed into Z-scores 
using the equipment-specific age- and sex-adjusted reference data for US Caucasian children; all subjects 
were of normal height186. Body composition was analysed to obtain lean body and fat mass. Calibration 
of the measurements was performed by using a spine phantom; inter-CV% for the phantom BMC, area, 
and BMD were 0.35%, 0.21%, and 0.41%, respectively. The reproducibility of the DXA measurement 
for bone, fat, and lean mass is 1.2%, 1.9% and 0.7%, respectively, in children between 10 and 18 years 
of age187. 
?
? ?
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9.3.5 Statistics?(I?IV)?
The Shapiro–Wilk test was used to test for normality, and nonparametric tests were used to determine 
associations between BTMs as they were not normally distributed (Shapiro–Wilk test<0.95). Glucose, 
insulin, adiponectin and all OC concentrations, and HOMA-IR were non-normally distributed and were 
analysed after logarithmic transformation.  
Most parameters for descriptive statistics are presented as geometrical mean values ± SD or SEM, when 
appropriate. Z scores for skeletal parameters are indicated especially in paediatric cohorts. A paired t test 
was used to detect longitudinal changes during OGTT in each variable. Spearman’s correlation was used 
to study the associations between OGTT-induced changes (Study I-III). Linear regression was used to 
study associations between different BTMs and between other parameters and/or sampling time-points. 
The difference between parameters for the Term and VLBW groups (Study II) were analysed with one-
way ANOVA. Standardised linear regression coefficients (?std) between the OGTT analytes or the 120 
min changes in the analytes were determined using linear regression. Multivariable regression analysis 
was used in all studies, adjusting for clinical characteristics such as age, gender, VLBW status or BMD.  
We used SPSS for Windows; versions between 16.0-21.0 (SPSS Inc., Chicago, IL) for statistical 
analyses, except for linear regression which were calculated using Statistica for Windows 7.1 (StatSoft 
Inc., Tulsa, OK). P values <0.05 were considered statistically significant.  
Also, the previously unpublished adiponectin data were used for simple linear regression and multiple 
variable analyses only after natural logarithmic transformation (concentrations non-normally 
distributed). 
? ?
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10. Results?
10.1 Clinical?characteristics?of?all?study?participants?(I?IV)?
The clinical demographic characteristics of all study participants are presented in Table?3. The overall, 
combined cohort (n=572) represents a diverse but singular population, in which the role of OC has now 
been characterised both as 1) a normative BTM reflecting the diverse stages of normal growth spurt 
through puberty and early adulthood, and 2) a potential key player in glucose homeostasis in apparently 
healthy individuals, but also in those with a history of childhood metabolic conditions such as morbid 
obesity.  
Subjects in Study IV were the youngest, with mean age of 13.8 years (for girls) and 12.5 years (for boys), 
representing conveniently the time around the achievement of mid-puberty status: mean age for mid-
pubertal groups was 12.8±1.27 years and 13.8±1.96 years for girls and boys, respectively. The mean age 
category enrolled represented also the most heterogeneous group of different stages of puberty (pre-, 
mid- and post- as displayed for our cohort in Figure?6), especially in boys. In this paediatric cohort with 
such large age-related disparity it was considered pragmatic to divide the cohort in more robust age 
categories for both sexes when defining age-specific reference ranges. The graphical presentation (Figure?
7) illustrates how the wide age range for girls (7A) can be divided into five balanced age categories (7B), 
in which the age-dependent increase in height (7C) or weight (7E) demonstrates an equal distribution of 
height SD (7D) or weight % (7F) across over all age categories. 
All cohorts enrolled represented essentially normoglycaemic individuals with no previously diagnosed 
impairment of glucose tolerance. In Study I, one subject with a normal baseline glucose value had an 
increased glucose value at 120 min (9.2 mmol/l) indicating signs of IGT but after repeated testing the 
120 min value was within normal limits. Many obese subjects in Study III presented with early signs of 
insulin resistance (as discussed later in 10.5.3). In the same study, even if the mean plasma glucose 
concentrations were similar between the groups at any assessed time point (AUC in repeated measures 
ANOVA; P=0.066), 3-fold higher serum insulin concentrations were observed in response to OGTT in 
obese subjects compared with controls (AUC in repeated measures ANOVA; P =0.003).?At 120 min 
glucose values were within normoglycaemic range (< 7.8 mmol/l) in all subjects. 
In general, even if normoglycaemic, subjects with VLBW had higher 2-hour insulin (p=0.001) and 2-
hour glucose concentrations (p=0.037) and marginally elevated fasting insulin (p=0.068) as compared 
with those born at term.   
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Figure?6:?Proportional?pubertal?stage?(pre?,?mid?,?post?)?status?for?girls?(G)?and?boys?(B)?per?age?
category.?
 
 
In Study IV, the mean serum 25-OHD (±SD) concentration, 42.5±12.46 nmol/l (range 17.0 nmol/l, 82.0 
nmol/l for all pooled girls and boys, n=171), was considered low, even insufficient, while apparently also 
reflecting the time-point of assessment, the winter period.?All study populations were also assessed for 
skeletal parameters, both BTMs and DXA-based estimates of specific skeletal sites such as LS or FN for 
Study II or WB Z score and/or WB BA, which are more appropriate for paediatric populations as those 
enrolled in Study III or IV. For Study IV, individuals with WB Z score beyond +2 or -2 were excluded. 
The mean results of the DXA analysis in addition to the anthropometric clinical characteristics confirmed 
that these study populations represented mostly apparently healthy individuals, children, adolescents and 
young adults, with normal bone metabolism.  
Presenting mean values of anthropometric or skeletal parameters for a heterogeneous, healthy and mostly 
growing paediatric cohort ranging from 7 to 18 years of age, as for Study IV and in Table?3, is only 
justified by the purpose of this general composite presentation of the overall demographics for the 
subjects enrolled for this research.?
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10.2 Serum?osteocalcin?levels?in?children,?adolescents?and?young?adults?(I?IV)?
The mean fasting OC and cOC concentrations are presented for all study cohorts in Table?3 and Figure?
8. In childhood, the OC and cOC values for both girls and boys reflect the expected BTM patterns for a 
normal pre-pubertal growth phase and new bone formation through modeling; the mean OC values were 
between 25-35 ng/ml, with mean cOC values incrementally, up to 10 ng/ml, higher. During the peak 
growth spurt for girls in age category of 11, the OC and cOC concentrations are elevated up to 350% vs. 
the corresponding concentrations during post-pubertal phase (age categories 17 and 19 in girls) or later 
in life as measured in the young adult cohorts. The normal OC and cOC concentrations for adult female 
subjects beyond age of 20 years stabilised around 9-10 ng/ml and 13-14 ng/ml, respectively. As reported 
for Study II, the fasting OC and cOC concentrations were statistically significantly affected by the 
VLBW status (p=0.027 and p=0.005 for OC and cOC, respectively) even if these differences might not 
be clinically relevant. 
The same pattern of OC dynamics was observed for boys and male subjects while the timing of the 
growth spurt and peak concentrations of OC and cOC in boys appear later than in girls, in the age category 
of 14 years. The cOC concentrations are raised up to 380% vs. those values determined as normal for 
young adult males. The elevated mean OC concentrations (mean 23.6 ng/ml) and also the highest SD in 
all OC categories (10.43) in age category 17 reflect the number of still mid-pubertal and growing boys 
in the same group.  
Mean age (19.3/19.4 years) in the ELLU cohort corresponds with the age category of 19 years for girls 
in Study IV while the overall OC and cOC concentrations in the ELLU cohort, both for those with a 
history of childhood obesity (total OC: 13.6±5.21 ng/ml) and for their controls (total OC: 17.6±9.62 
ng/ml), seem slightly higher vs. the age category 19 or the Study I/II cohorts. This type of variation 
confirms how sensitive the BTM assays are and how even the slightest deviation or difference in the 
analysis methodology, or other environmental factor as discussed previously, may alter the results of the 
apparently same analysis on a different day or cohort.   
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Figure?8:?Overall?presentation?of?pooled?mean?serum?OC?(solid?marker?fill)?and?cOC?(no?marker?fill)?
concentrations?for?all?study?cohorts:?paediatric?normal?reference?range?cohort?per?age?categories?(8?
19:?Study?IV,?females?subjects?with?pink?diamonds?and?males?subjects?with?red?rectangles),?ELLU?cohort?
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10.3 Effect?of?acute?glucose?load?during?OGTT?(I??III)?
10.3.1 Impact?of?OGTT?on?serum?total?OC?and?cOC?
The mean baseline concentrations of total OC and cOC are displayed for all study cohorts in Table?3. As 
analysed in detail for Study I, the observed OC levels were independent of the time of collection: 
standardised regression coefficients for OC levels and sampling time (between 8:05am and 11:02am) 
were for OC 0.33 (p=0.128) and for cOC 0.40 (p=0.06). 
Overall, the OGTT induced a significant decrease in both OC and cOC concentrations for all study cohort 
groups (Figure?9). There was a strong association between the changes in total OC and cOC (Study I: 
Spearman’s correlation, r=0.83, p< 0.001) while the magnitude of the reduction from baseline varied 
between cohorts (Study I vs. Study II-III) and within cohorts (Study III obese vs. controls). Unexpectedly, 
the most pronounced decline in OC and cOC concentrations were induced in the Study I pilot population 
evaluated:  the median (interquartile range; IQR) decreases for OC and cOC were -32.1% (-37.9 ? -19.6) 
and -34.4% (-39.8 ? -22.2), respectively. These samples were collected from the firstly enrolled 23 
subjects, otherwise representative of the overall pooled Study I-II population and thus not providing no 
physiological reasons for the more pronounced reduction in OC/cOC levels vs. the overall cohort.  
However,  the dynamics of total OC and cOC during OGTT demonstrated an unexpected pattern between 
the groups in Study III when the maximum decreased in obese subjects was limited to -13.1% and -10.9% 
for total OC and cOC, respectively, while the equivalent reductions in the control group were 
significantly higher, i.e. -21.1% (P=0.022) and -16.5% (p=0.055), respectively. Nevertheless, due to the 
already lower baseline OC levels (Table?3) the relative decrease in total OC during OGTT was less 
distinct in obese subjects vs. controls (p=0.029). There was no difference between groups regarding cOC 
concentrations (p=0.139). In addition, even if the postprandial total OC was suppressed, the effect 
appeared later in obese subjects than in controls. 
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Figure?9:?The?OGTT?induced?effect?on?serum?total?OC?(solid?colour)?and?cOC?(striped).?Assessment?for?
study?I?(dark?red)?and?Study?II?(red)?cohorts?at?120’?and?Study?III?(dark?brown?for?obese?and?lighter?brown?
for?controls)?at?the?time?of?maximum?postprandial?effect?(60’?120’?depending?on?the?variable)?
?
 
10.3.2 Effect?of?OGTT?on?other?BTMs?(I,?III)?
In Study I, the only post-ingestion time-point gauged for BTMs was 120’ while in Study III the OGTT 
also included 30’, 60’ and 90’ time-points. Figure?10 summarises the effect of OGTT on reference BTMs 
in Study I and III. 
For Study I, the OGTT resulted in a statistically significant decrease from baseline to 120’ in all evaluated 
BTMs (paired t-test, p< 0.001 for all variables). The reductions (IQR) for the resorption markers ?CTX-I 
and TRACP5b were 61.4% (68.5, 53.0) and 44.5% (48.3, 40.2), respectively, while the bone formation 
marker PINP was reduced with -26.8% (33.2, 19.2). In Study III the most consistent reductions were being 
observed for CTX additional to OC, with maximum reduction of 52% for CTX.  
As expected, all BTMs in Study III responded rapidly within 30 minutes and demonstrated maximum 
drops from baseline between 60 and 90 minutes (p<0.02 for all with no difference between the studied 
groups [p-values between 0.5 and 0.7 for the comparison]). The post-OGTT changes in Study I for ?CTX-
I and TRACP5b were not associated with changes in serum OC or serum cOC (r=0.22, p=0.31 and r=0.26, 
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p=0.24, respectively) while the change in ?CTX-I was moderately associated with reduction in PINP 
(r=0.42, p=0.047) and TRACP5b levels (r=0.44, p=0.037).  
None of the OGTT-induced changes in BTMs were associated with OGTT-induced changes in insulin or 
glucose alone in either Study I or in Study III (p>0.05 for all). However, inverse associations between 
acute (r= -0.315, p=0.020) and steady-state (r= -0.380, p=0.007) responses of BAP to glucose were 
observed in Study III; the association remained significant after adjusting for insulin (r= -0.301, p=0.027). 
Correspondingly, acute change in glucose was inversely related to overall response (measured as AUC) 
in CTX but only with a borderline level of significance (r=-0.208, p=0.059).  
 
Figure?10:?Impact?of?acute?glucose?load?(standard?OGTT)?on?different?BMTs?in?Study?I?at?120’?(striped)?
and?Study?III?(maximum?observed?drop:?solid?colour).?
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10.3.3 Osteocalcin,?glucose?and?insulin?(II)?
In Study II, fasting glucose and insulin concentrations were within normal ranges in both VLBW and 
control groups while insulin levels were marginally higher in VLBW subjects (+11%, p=0.068) when 
compared to those born at term. This difference between groups was also statistically significant between 
the female VLBW subjects and their controls; females with VLBW had higher baseline insulin values 
(5.8 vs. 5.0 mU/L, p=0.045). There was no difference in fasting glucose levels between the groups 
(p=0.24) or between the genders. Yet, at 120’ all subjects with VLBW had significantly higher 
unadjusted insulin (+30.5%, p=0.001) and glucose concentrations (+5.5%, p=0.037) than those born at 
term as also previously reported by Hovi et al122.  
In the overall cohort, fasting total OC and cOC were negatively correlated with fasting insulin levels 
after adjustment for age, gender, VLBW status and BMD (r= -0.182, p=0.009 and r= -0.283, p<0.001, 
respectively). The observed correlation persisted as significant even after adjustment for lean body mass 
(r= -0.242, p<0.001) and WB fat% (r= -0.144, p=0.028). The correlation between fasting insulin and OC 
was similar in both groups, although the association parameters were generally stronger in the VLBW 
group. There was no significant association between insulin and total OC when the correlations were 
further adjusted for body fat%. 
During OGTT, the correlation between the changes in glucose and insulin concentrations at 120’ were 
as expected significant (r= 0.663, 95% CI 0.582, 0.745, p<0.001). Total OC and cOC were only modestly 
associated with postprandial levels of glucose (p=0.022 and p=0.034, respectively) but not with insulin 
(p=0.54 or 0.24, respectively). Figure?11 displays graphically the lack of correlations between these key 
parameters, total OC and cOC (at 0’ and 120’) and postprandial insulin levels.   
The lack of existing, validated methods for the accurate analysis of the proportion of uncarboxylated OC, 
unOC, has limited investigation of the unOC values derived from theoretical estimates based on the total 
OC and cOC measurements. In our analysis set, fasting insulin levels correlated positively with 
calculated proportion of unOC (r=0.176, p=0.001) and this correlation was significant also after 
adjustment for age, gender and VLBW status (r=0.193, p<0.001). Against the proposed theory, the total 
OC correlated negatively and the estimated unOC positively with fasting insulin when adjusted for age, 
gender, VLBW status and lean body mass (r=-0.156, p=0.021 and r=0.153, p=0.007, respectively). 
? ?
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Figure?11:?Correlations?(unadjusted)?between?0’?or?120’?serum?total?OC?and?cOC,?and?postprandial?
120’?insulin?concentrations.?The?lack?of?association?between?postprandial?insulin?levels?and?serum?OC?
concentrations?(total?or?cOC,?at?0’?or?120’)?indicates?that?insulin?is?not?a?key?mediator?of?acute?glucose?
homeostasis?(all?p=ns).?For?details?of?correlation?parameters,?see?text.?
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10.4 Osteocalcin?and?BMD?(II)?
In the Study II population, the mean areal LS Z-score values were significantly lower in the VLBW 
subjects than in those born at term (-0.94± 0.98 vs. -0.42 ±1.05, respectively, p<0.001). Similarly, the 
aBMD Z score for FN was reduced in the VLBW cohort (-0.48 ± 0.86) while it was normal in those born 
at term (0.14 ± 0.98, difference p<0.001). Consistently, the fasting OC and cOC concentrations were also 
significantly higher in subjects born with VLBW vs. their controls (ANOVA, p=0.027 and p=0.005, 
respectively). Independently, both groups showed a similar and statistically significant correlation 
between the total OC and LS areal BMD (pooled): r=-239, p<0.001 (Figure?12).  
In a multiple regression model for paediatric population (Study IV) the WB BMD Z score was not an 
independent predictor of serum total OC (p=0.404) or cOC (p=0.932) concentrations. 
?
Figure?12:?Association?between?total?OC?and?LS?aBMD?Z??score?in?overall?population?with?pooled?
young?adults?(Study?II):?controls?(dark?red?circles)?and?subjects?with?VLBW?(pink?rectangular?
markers).?
?
?
?
?
r=?0.239,?p<0.001?
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10.5 OC?and?markers?of?metabolic?or?glycaemic?disturbances?(I?III)?
10.5.1 HOMA?and?serum?insulin?(II?III)?
Fasting serum insulin is a driver of homeostasis model assessment of insulin resistance index HOMA-
IR181. In Study II cohort, the assessed HOMA-IR values were normal: 1.0 ± 1.75 and 1.12 ± 1.85 for 
females and males, respectively. The difference between HOMA values in VLBW (1.37 ± 0.86) and 
control (1.27 ± 1.02) groups in fasting state did not reach statistical significance (ANOVA, p=0.342). 
HOMA-IR strongly correlated with fasting OC and cOC, independent of age, gender, VLBW status and 
height (p<0.001 for all correlations) and independent of lumbar spine BMD (r=0.180, p=0.010 and r=-
0.277, p<0.001 for total OC and cOC, respectively). The association between HOMA-IR and total OC 
was no longer significant (p>0.05) when further adjusted for BMI, whereas association with cOC 
remained significant (r=-0.126, p=0.038).  
In Study III the baseline HOMA values indicated elevated insulin resistance in obese subjects and was 
significantly higher in obese (3.89 ± 2.36) vs. controls (1.46 ± 0.77), p<0.001.  
 
10.5.2 Adiponectin?(II?III)?and?leptin?(III)?
The mean adiponectin concentrations for the Study II (unpublished data) and Study III cohorts are 
presented in Table?4. The levels of adiponectin were similar for both VLBW and control groups, falling 
in between the mean values for obese and control subjects in Study III. There was a 3.6%, non-significant, 
difference in the adiponectin concentrations between the control and VLBW cohorts in favour of the 
VLBW cohort. The adiponectin concentrations were significantly higher in the control subjects of Study 
III vs. obese (p=0.004).  
 
Table?4:?Adiponectin?and?leptin?concentrations?in?Study?II?and?III?
cohort 
STUDY II STUDY III 
VLBW Control Obese Control 
Adiponectin (SD), ng/ml 8116 (1577) 7833 (1641) 7734 (3115) 11625 (6499)
Leptin (SD), pg/ml - 51887 (28990) 8875 (6995) 
 
In Study III, total OC and cOC were inversely associated with adiponectin concentrations at baseline 
(Spearman correlation -0.418, p=0.017 and -0.452, p=0.011 for OC and cOC, respectively). In Study II 
a simple, unadjusted linear regression model demonstrated no significant association between 
adiponectin concentrations and serum levels of the tested candidate influencing the energy metabolism, 
cOC (r= -0.055, p=0.321). In a multiple regression analysis when adjusting for clinical characteristics 
such as age, sex, anthropometric or parameters reflecting the body composition or skeletal health, there 
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was a trend (p=0.072) towards an association between cOC and adiponectin in all subjects. Otherwise, 
as expected, adiponectin was associated with age, sex and BMI (all p<0.0001) while also LS aBMD Z 
score (p=0.008) seemed to correlate with adiponectin concentrations.   
Adiponectin was not related to any BTMs in the obese cohort (all p=ns) in Study III, but in the control 
group its concentrations were inversely related to all measured BTMs (total OC, cOC, BAP, PINP, 
TRACP-5b; all significant), except CTX (p=0.071). In the combined cohort, adiponectin was only related 
to BAP (Spearman correlation -0.399, p<0.001) and tended to relate with PINP (-0.249, p=0.051). In 
both groups and in the combined cohort, adiponectin was inversely associated with insulin (-0.568, 
p<0.001) and glucose (-0.373, p=0.002).  
Leptin concentrations in Study III inversely associated with those of adiponectin (-0.304, p=0.012) in the 
overall pooled population but not for obese or controls alone. It was significantly inversely correlated 
with all of the assessed BTMs in obese subjects and most, except for TRACP-5b, in the control group. 
In the combined group, BAP was no longer significantly associated with leptin.  
?
10.5.3 Childhood?obesity?and?OC?(III)?
Subjects with a history of childhood obesity before the age of 7 years were still obese (BMI > 40 kg/m2) 
as adolescents and during early adulthood (mean age 19 years), and 55% of the subjects presented with 
early signs of increased insulin resistance and hyperinsulinemia. In this group, the elevated fasting insulin 
(>12 mU/l), lower adiponectin (7734±3115ng/ml vs. 11625±6499ng/ml, p=0.004 for obese and controls, 
respectively) and 5-6-fold elevated leptin concentrations (p<0.001) together with more frequent smoking 
(> 1/3 being smokers), in addition to obesity and yet to be confirmed pre-diabetic status, predispose the 
subjects to an early risk of acquiring T2DM even with or without the speculated effect of OC.  
In Study III, as concluded before, the obese subjects had lower baseline concentrations of BTMs, 
including OC and cOC, (other than BAP) compared with normal weight subjects (Table?3). As expected, 
acute glucose intake suppressed various BTMs as a sign of reduced bone turnover during OGTT but not 
the total OC behaved differently in controls vs. obese subjects (see 10.3.1). Additionally, the postprandial 
effect on total OC appeared unexpectedly later in obese subjects than in controls. Therefore, again, the 
results of Study III do not directly support the previously hypothesised presence of a short-term feedback 
loop between OC and energy metabolism in subjects with predisposition to or presence of a metabolic 
condition. 
?
? ?
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10.6 Normal?paediatric?reference?ranges?(IV)?
10.6.1 Serum?osteocalcin?
The mean overall OC concentrations for girls and boys in Study IV are presented in Table?3. All 172 
subjects in Study IV had serum samples drawn at fasting state and the mean (±SD) total OC and cOC 
values per age category for both sexes are presented in Figure?13. As expected, the peak serum total OC 
values per age category were observed at different time-points for the two sexes: 38.7± 11.47 ng/ml at 
11 years for girls and 38.8± 9.43 ng/ml at 14 years for boys. The cOC concentrations followed 
consistently the same pattern (Figure?13). The largest variation within an age category (measured with 
the highest SD) was observed in age categories 14 and 17 for girls and boys, respectively. This 
observation is probably related to the mixed pubertal status in these categories vs. the earlier or later age 
categories.   
As expected, serum OC and cOC increased profoundly with puberty, with up 350-450% vs. the final late 
adolescence concentrations, and the values correlated with the pattern of pubertal growth, which started 
to decline earlier in girls (after 11 years) than in boys (after 14 years). The graphical presentation (Figure?
14) of two age categories, 11 and 14, which coincide with the attainment of mid-puberty status, 
demonstrates how the timing between the age category-dependent elevation and decline in total serum 
OC varies between sexes, showing an opposite direction of dynamics on the level of the overall cohort, 
from lowest to the highest observed values, for girls vs. boys. The dynamics of the development of the 
total OC and cOC concentrations from childhood through adolescence are described in details in Section 
10.2.  
?
Figure?13:?Mean±SD?serum?total?OC?and?cOC?concentrations?per?age?category?for?both?girls?(darker?
red)?and?boys?(pink?tones)?
 
8 11 14 17 19
GIRLS?OC 33 38.7 28.6 13 10.8
GIRLS?cOC 41.5 45.8 35.8 16.6 13.1
BOYS?OC 25.5 31.5 38.8 23.6
BOYS?cOC 33.6 40.6 48.2 29.4
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Figure?14:?Dynamics?of?the?opposite?trends?for?minimum,?25th,?50th,?75th?percentiles?and?maximum?
values?of?serum?total?OC?for?girls?(dark?red?tones)?and?boys?(pink?tones)?for?age?categories?11?to?14.?
?
 
 
For the purpose of defining normative and clinically useful paediatric reference intervals the total serum, 
carboxylated and urinary OC values, Tukey’s Hinges percentiles (25th, 50th and 75th) and graphical 
presentation of the combined minimum, maximum values for age categories, and separately for both 
sexes were prepared. The complete data are not shown here (refer to the submitted manuscript; see Figure?
14 for minimum, 25th, 50th, 75th percentiles and maximum values for age categories 11 and 14 for total 
OC). 
In a multiple regression analysis, the independent determinants of OC concentrations were age (p<0.001) 
and height (p=0.003) while cOC values were additionally influenced by weight (p=0.037) and PTH 
(p=0.023). Weight and Vitamin D concentrations demonstrated borderline significance for OC in the 
same analysis (p=0.059 and 0.076, respectively).  
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10.6.2 Urinary?mid?fragment?osteocalcin?
Despite the presumed acceptance for collection of urinary samples (vs. serum samples), urinary samples 
for assessment of U-midOC were missing from 9 girls and 4 boys, i.e. the reference values were defined 
only in 159 children and adolescents. All the crude U-midOC values were corrected for urine creatinine 
before analysis. The mean (± SD) concentrations for each age category and for both sexes are presented 
in Figure?15.
Contrary to the serum OC and other BTMs, the creatinine-corrected U-midOC values were already 
elevated in pre-pubertal subjects, equally in girls and boys, in the lowest age category (8 years). Similarly, 
the U-midOC concentrations were comparable between both sexes in age categories 8 and 11 while the 
concentrations declined earlier in girls vs. boys, following the pattern of the serum OC/cOC values. In 
general, there was a significant correlation between the serum total or cOC and U-midOC concentrations 
in the overall pooled cohort for girls (Spearman correlation, all p-values <0.001), while for boys the 
pooled U-midOC concentrations lacked correlation between total serum OC and cOC concentrations 
(r=0.12 and r=0.234, for OC and cOC, respectively, p=ns). The correlation between the total serum, cOC 
and U-midOC progressively improved with increasing age especially in boys and reached significance 
in the oldest age (17) category (correlation for U-midOC: r=0.692, p=0.009 and r=0.610, P=0.027 for 
total OC and cOC, respectively). 
?
Figure?15:?Mean?(±?SD)?urinary?mid?fragment?concentrations?for?girls?(red)?and?boys?(brown)?per?
age?category?
?
?
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U-midOC as a parameter was more robust vs. serum OC variants in a multiple regression analysis, and 
in the crude analysis based on evaluation of age categories, and only age (p=0.005) and puberty (p=0.030) 
were displayed as independent determinants of U-midOC. 
?
10.6.3 Other?BTMs?
The mean ±SD reference BTM data for PINP, ICTP, urinary NTX and ALP are presented for both sexes 
per age category in Figure?16. The concentrations of all these reference BTMs increased with, or were 
already elevated prior to puberty, in both girls and boys. The BTM dynamics also correlated with pubertal 
growth with concentrations starting to decline earlier in girls (after 11 years) than in boys (after 14 years) 
following the pattern of OC and cOC. Supporting the DXA findings the reference BTM concentrations 
(PINP, ICTP, uNTx and ALP) for all the age categories confirmed that the subjects had a normal bone 
turnover at the time of evaluation, despite the generally low Vitamin D levels. Independent of the Vitamin 
D tertile, the reference BTMs were strongly associated with OC, cOC and U-midOC (p<0.001 for most 
BTMs, only ICTP not being associated with U-midOC in the highest Vitamin D tertile). 
?
Figure?16:?Paediatric?mean?±SD?reference?BTM?concentrations?for?PINP?(A),?ICTP?(B),?U?NTX?(C)?and?
ALP?(D)?in?girls?(pink)?and?boys?(dark?red)??
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11. Discussion?
The overall purpose of this research was to explore whether, how and potentially why a bone-specific 
molecule, such as OC, is or is not involved in the suggested bi-directional regulation of energy 
metabolism.  Additionally, we pursued to establish sex- and age-specific local Finnish BTM reference 
intervals, focusing on urinary, serum total and carboxylated OC levels, in healthy Finnish children and 
adolescents. As the proposed association between OC and glucose homeostasis has been explored mainly 
retrospectively, in post hoc analyses and in cohorts that included patients with multiple confounding 
factors, it was important to address the hypothesis in healthy young adults or those with metabolic 
syndrome or signs of it but no diabetes. Aspects related to the timing and magnitude of the changes in 
glucose but also OC homeostasis, whether these changes are biologically significant in normoglycaemic 
subjects, and how these changes associate with skeletal parameters, were still to be explored.  
In addition, there has been inopportune use of causal language and lack of appropriately designed 
prospective studies to generate evidence regarding the role of OC in regulation of human glucose 
metabolism. Based on the present evidence, it is indeed debatable if any form of OC has potential as a 
therapeutic target for regulation of glucose metabolism in humans. 
 
11.1 Translating?science?from?mouse?to?humans?
The appropriateness of the engineered mouse models for the study of OC as a therapeutic target in 
humans appears ambiguous due to various reasons. In normally fed mice, circulating OC is fully 
carboxylated, whereas in humans the proportion of circulating OC is lower, about 20%146 compared with 
other species and only half of the circulating human OC is carboxylated188.?The suggested, rather modest, 
changes in the concentrations of unOC in mouse models159 indicate a very narrow therapeutic range of 
effect in animals, which has limited applicability in humans due to species-specific differences.  There 
are also other critical species-specific differences in OC between mice and humans, such as only limited 
(60%) homology between the genes encoding OC in mice and humans189. In addition, the role of 1,25-
Vitamin D varies in the regulation of the OC gene between these two species; the single copy of the OC 
gene in humans is upregulated whereas the three murine copies of the gene are downregulated by 1,25-
Vitamin D146,190. In conclusion, these fundamental species-specific differences in the OC protein 
necessitate caution when translating the claims based on engineered mouse-models into humans.  
 
11.2 Glucose,?insulin?and?OC?
11.2.1 Impact?of?acute?glucose?load?on?markers?of?bone?turnover?
We studied the suggested association between energy metabolism and OC and its bi-directional 
regulation by exploring the impact of acute glucose load, OGTT, on OC, cOC and other BTMs in healthy 
young adults and those with a history of childhood obesity. Our results indicate that an acute glucose 
load induces a significant and rapid decrease in serum OC, its carboxylated form and in markers of both 
bone resorption (?CTX-I, TRACP5b) and formation (PINP, BAP). The observed OGTT-induced 
decreases in these different bone-derived proteins are at least partially independent of each other, 
demonstrate different timing of maximum suppression and, at times, even inconsequent patterns between 
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the studied populations. Whether these acute changes are directly insulin-induced or mediated by OC or, 
as suggested, by unOC, remains unclear. 
Different bone markers and their serum or urine levels reflect different steps of the constantly ongoing, 
coupled bone remodeling191. BTMs reflect the rate or speed pf enzymatic activity of the diverse bone 
cells, excess products from the formation or fragments released during the degradation of bone matrix 
components192, 193, and thus circulating proteins or their fragments detectable in serum can be derived 
from various sources. Altering gene expression might influence the de-novo biosynthesis of the intact 
proteins and most BTMs demonstrate dependence on circadian rhythm, diet, age, concomitant diseases 
and medication and many more21. Thus, impact on any single factors on levels of BTMs should be 
interpreted with caution and concomitant assessment of multiple markers, preferably both resorption and 
bone formation BTMs provide with a more reassuring perspective. However, as observed in our studies, 
acute suppression of bone turnover and its markers after intake of nutrients is not a new phenomenon; 
diet-induced, non-insulin-mediated changes are usually greatest in the most commonly used BTM, serum 
?CTX-I levels194,195,196 and of smaller magnitude195,197 or not statistically significant194, in serum total 
OC. Both an OGTT and intravenous glucose tolerance test (IVGTT) have induced a decrease in CTX 
and total OC concentrations in otherwise healthy postmenopausal women while OGTT induced a 
significantly larger decrease in CTX than the IVGTT196. Whether the differences observed between 
OGTT and IVGTT were related to the dose of glucose or route of administration affecting the 
gastrointestinal incretin effect after oral dosing, cannot be determined. In our studies, OGTT-induced 
suppression in CTX was approximately 50-60%, depending on the population, and similar to the effect 
reported previously by others as a result of food intake195,198 and an oral glucose load195.  
Feeding has been reported to have very little effect on serum TRACP-5b when it was analysed at fed and 
fasting state199. Interestingly, in our young adults (Study I) an OGTT induced a significant reduction 
(median -44%) in serum TRACP5b levels while the adolescents with history of childhood obesity 
displayed a more typical, diminished response in TRACP-5b. Oral glucose load induced a smaller but 
highly significant reduction in PINP and a variable response in OC. Changes observed in PINP and OC 
were highly correlated to each other, but appeared to be independent of the suppression of bone 
resorption, as change in CTX-I was only moderately associated with the reduction in PINP and not 
associated with the changes in OC. No associations were observed between changes in TRACP5b and 
bone formation markers. Thus, these rapid changes cannot be explained by coupling between formation 
and resorption during the 120-minute time period. 
Insulinotropic peptides, such as the already therapeutically utilised glucagon-like peptide -1 (GLP-1), 
GLP-2 and glucose-dependent insulinotropic peptide (GIP) have been studied as potential mediators of 
the postprandial reductions in BMTs. These incretins are released from the duodenal K cells in response 
to carbohydrate intake200 and are known to be induced by feeding and, even more pronouncedly, by an 
OGTT as demonstrated in the classic incretin test by Nauck et al201. In animal studies, however, GIP has 
been observed to both inhibit bone resorption and stimulate bone formation202. Previous studies in healthy 
subjects have shown no direct effect of GLP-1 or GIP on serum total OC after ingestion of macronutrients 
or after exogenous parenteral administration of incretins194,203. Only the bone resorption marker CTX 
was reduced as a response to a macronutrient meal or to exogenous GLP-2 infusion. These studies 
exclude both GIP and GLP-1 as key mediators for the immediate reduction in bone resorption after a 
meal203.  Thus, the OGTT-induced suppression of serum OC and cOC observed in these studies is likely 
to be mediated via a different mechanism. On a general note, direct comparisons of the mechanisms and 
effects of an OGTT and ingestion of macronutrients on bone are debatable because regulation of glucose 
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metabolism under rapidly applied, non-physiological glucose load might be induced by different 
mechanisms than under more physiological intake of nutrients during a meal.  
The observed inverse associations between the glucose levels and bone-formation marker BAP or the 
glucose and resorption marker CTX in our study indicate that postprandial hyperglycaemia or OGTT-
induced changes in general suppress bone turnover, independent of the utilised BTM. Rather than 
exploring the regulatory role of a single bone-derived molecule, such as unOC, in glucose homeostasis, 
the association between OC and glucose may be indicative of a universal role of bone in glucose 
impairment and diabetes175. Similarly, earlier studies have proposed that hyperglycaemia may contribute 
to lower bone turnover204 and favour differentiation of mesenchymal stem cells into adipocyte lineage 
instead of bone cells205. The unique response of OC to glucose during OGTT could have a logical 
explanation as OC is considered a secondary marker of late stages of bone turnover, produced by mature 
osteoblasts during the mineralisation process to stabilize the structure of the bone mineral, HAP206. 
Deletion of insulin receptor specifically in osteoblasts has been demonstrated to result in decreased 
secretion of OC in mice207 and thus the delayed decline in OC noted in young but obese subjects could 
result from already suppressed baseline bone turnover, which in turn was further suppressed during 
OGTT.  
 
11.2.2 Studying?insulin?signalling?and?role?of?OC??
When evaluating the impact of glucose on post-load OC and cOC values in our main study population, 
these parameters correlated only weakly with postprandial glucose or insulin values indicating that OC 
does not seem to be the main mediator of acute glucose regulation in humans during OGTT. As discussed 
above, this is contradictory to the data from animal studies suggesting that insulin signalling in 
osteoblasts increases the secretion of OC, promotes glucose homeostasis via unOC and may thus prevent 
the development of insulin resistance, glucose intolerance and abnormal weight gain132,154,157. Several 
mechanisms based on murine data have been proposed, including stimulation of osteoblast differentiation 
and OC production, and increased release of unOC from the bone matrix due to increased bone resorption 
via alterations in RANK-RANKL-OPG pathway154,155. Yet, based on our findings and those from others 
(Table?1) it is increasingly unclear if a similar regulatory system is present in humans146,147.  
Our results have also raised a question about the best clinical method to evaluate the effect of OC on 
glucose homeostasis and especially physiological insulin release. As it is not biologically feasible or 
ethical to alter the levels of OC or to introduce a knock-out design in human subjects, the hypothesis of 
a bi-directional regulation of energy metabolism by bone can only be studied by altering the magnitude 
of the energy load instead. Alternatively, the hypothesis could also be explored by including subjects 
with potential predisposition to an altered OC metabolism or carboxylation status such as cohorts of 
prematurely born subjects with documented impairment in bone metabolism. However, it is not generally 
known whether clinically meaningful changes in markers of bone homeostasis or presumably rapid effect 
of insulin should be studied in a standardised 2-hour OGTT. On the other hand, more sophisticated 
approaches with continuous glucose monitoring e.g. in clamp studies in humans isolating the effect of 
insulin on bone turnover markers have also failed to confirm the effect of physiological changes in insulin 
on bone metabolism197,208. The same applies to clinical studies; as an example, in a cross-sectional study 
in an elderly population, the explored effect of OC was significantly correlated with insulin resistance 
but no association with insulin secretion was observed140. Our results do not, however, exclude the 
possibility that insulin-induced OC may regulate glucose and bone metabolism over a longer or shorter 
period of time than the intervals used in these studies. Our data simply indicate that, in humans, OC and 
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cOC levels rapidly and significantly decrease following the glucose load, but the magnitude or the timing 
of the change is not associated with increases in insulin levels.   
In summary, our results confirm that, in humans, acute postprandial changes in glucose homeostasis are 
still primarily regulated by the previously well-established physiological, non-skeletal and endocrine 
regulation pathways beyond those suggested for inclusion of OC209,210,211. The difference between the 
results observed in engineered knockout mice and in humans regarding the proposed role of OC in 
regulation of glucose homeostasis can potentially be attributable to the species-specific differences in 
OC189,190. The regulatory role of bone metabolism and, in particular, OC on glucose and insulin 
metabolism may also be different in acute and chronic metabolic challenge situations in humans.  
?
11.2.3 VLBW?status,?glucose?and?OC?
As only a limited number of studies have evaluated bone metabolism in VLBW subjects, the selection 
of our cohort with predisposition to a presumed impairment in OC metabolism provided additional 
opportunities for mapping the bone health of VLBW subjects beyond the general research question 
regarding the endocrine role of OC. Some studies have reported increased OC in male VLBW subjects212 
while, when exploring BTMs, another study identified no significant differences in formation or 
resorption markers213. In our study, OC and cOC were higher in subjects born with VLBW, and elevated 
OC levels could partially explain the observed decreased insulin sensitivity in VLBW subjects. Our 
finding, again, is somewhat contradictory to previous, mostly preclinical findings in mice on the role of 
OC in energy metabolism132,154,157.  
The baseline insulin and OC values were higher in female VLBW subjects than in females born at term 
but as previously reported, there is no general, significant interaction between genders in this VLBW 
cohort122. Our data indicate that the gender-specific differences do not significantly impact the suggested 
role of OC in acute postprandial glucose regulation. Subjects with VLBW are smaller, shorter and have 
lower BMI than their peers, and thus, the glucose load and total dose of glucose is proportionally higher 
for them. Also subjects born at term (but small for their GA) have been shown, in observational studies, 
to present with signs of impaired glucose regulation in adulthood214,215. VLBW subjects have reduced 
BMD as young adults. This might be due to their smaller size even if the measurements are corrected for 
bone size by estimation of volumetric bone density123,213. However, additional adjustment for 
anthropometric or other baseline clinical characteristics such as BMI, lean body mass and fat-% did not 
significantly alter the results, and thus, changes were mainly not attributable to body size or body 
composition. This is in agreement with results indicating that early signs of decreased insulin sensitivity, 
body size and composition did not explain the difference in regulation of insulin213. 
 
11.3 Effect?of?metabolic?impairment?on?bone?
During?hyperglycaemia?
Patients with T1DM have inadequate accrual of peak bone mass and impaired bone formation216, while 
T2DM patients typically have aberrant, either increased or decreased BMD217. When studying the basic 
physiological effect of any bone-derived components on energy metabolism or glucose on BTMs, it is 
crucial to exclude the potential metabolic confounders by selecting an apparently healthy 
normoglycaemic population, such as our young adults with or without a history of VLBW. Additional 
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confounding factors, such as T2DM -related comorbidities and complications, might influence BTMs, 
and some of the administered anti-hyperglycaemic medications such as thiazolidinediones shift the 
development of the mesenchymal stem cells and increase fracture risk in subjects with glucose 
impairment or T2DM218. In our cohort of subjects burdened by childhood obesity, the effect of the past 
metabolic disturbance was displayed as reduced BTM levels at the time of evaluation. Generally, lower 
BTMs have been observed in patients with T2DM vs. T1DM219,220. Although it is unknown why bone 
turnover markers are lower in patients with T2DM it is speculated to be related to the insulin resistance 
characteristic of obesity and T2DM219. 
The sustained elevated plasma glucose levels may affect OC and other BTMs directly or through 
mechanisms of insulin, incretins or other gastrointestinal hormones. This secondary effect to glucose and 
elimination of the effect of the OGTT has been demonstrated with octreotide, an inhibitor of insulin 
effect, incretins and gastrointestinal hormones195. Alternatively, insulin-mediated glucose uptake in 
osteoblasts and osteoclasts might also directly decrease the BTMs. Ominously elevated glucose levels, 
which can only be tested in in vitro setting, can be used to feature the effect of glucose on bone turnover. 
Multiple mechanisms exert the deleterious effect of high glucose on markers of bone turnover221,222,223. 
Sustained hyperglycaemia may affect the bone by suppressing bone resorption, increasing production of 
un-mineralised bone matrix or decreasing the degree of mineralisation224,225. Such processes can be 
assessed by determining the rate of pit formation in osteoclasts, production of Type I collagen in 
osteoblasts or by measuring ALP. Hyperglycaemia and advanced glycation end products (AGEs) can 
also promote the apoptosis of osteoblastic cells226,227. It must, however, be kept in mind that these 
dramatically increased glucose levels used in experimental setting are non-physiological for most of the 
diabetes patients under treatment (over 30 mmol/l or beyond), and studies using modestly elevated, but 
unfortunately not so uncommon, glucose concentrations of 10–15 mmol/l of glucose, are indicated.  
In T2DM patient populations, pronounced glycaemic variability, due to lack of sufficient glycaemic 
control or treatment-emergent fluctuation of daily glucose values is commonly observed228. Relevant 
glycaemic variability might also be reflected in the pattern of regulation of bone turnover in subjects with 
diabetes: inducing a state of cyclically varying bone turnover, where bone turnover is decreased at high 
glucose levels and normal at normal glucose levels. In this context, the assessment of HbA1c value as a 
sign of glycaemic impairment may not be as relevant as the instant glucose value, and assessment of 
variability at the time of blood sampling, such as during OGTT, displays the dynamics of the BTMs195,196. 
The HbA1c only reflects the average blood glucose concentration during the last 4-12 weeks and even if 
the value is weighted towards the last 2-4 weeks, reliable signs of change can be demonstrated at earliest 
from 20 days onwards (when e.g. efficacious glucose lowering is being implemented)229 while the plasma 
glucose values may at times during these 3 months be variably high or low, especially at fasting state. 
Thus, an association between a BTM and HbA1c values at a randomly chosen time-point might be of 
limited relevance.  
In subjects with T2DM, adiposity, through inflammatory cytokines, adipokines and free fatty acids has 
a long-term detrimental effect on bone but may also give rise to a chronic low-grade inflammation that 
may additionally suppress bone turnover and lower BTMs. A significant, negative correlation between 
BAP and tumour-necrosis factor alpha (TNF-?) has been shown, whereas correlations between OC and 
inflammation markers all were insignificantly negative230. In our cohorts, the relationship between OC 
and adiponectin was also unclear. Another study yielded contradictive results; OC was negatively 
correlated with inflammatory markers such as interleukin-6 and high-sensitivity CRP (hs-CRP)231. As 
the role of chronic inflammation and its effect on bone in subjects with T2DM is still under investigation 
the available evidence is relatively scant. 
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Changing?glycaemic?control?and?pre?diabetes?
On the other hand, improved glycaemic control and return closer to normoglycaemic range might 
stimulate osteoblastic differentiation and enhance bone formation. In patients with T2DM, total serum OC 
and its ratio against BAP (OC/BAP) correlated negatively with HbA1c values and positively with IGF-1 
in Japanese male subjects120. However, there are several studies which have shown low, normal and high 
IGF-1 levels in obese, normoglycaemic subjects with different degrees of insulin resistance, and thus the 
correlation with  IGF-1 deficiency might not be the only relevant mediator between glucose and bone 
metabolism232,233,234,235. Studies with obese adolescents presenting with metabolic syndrome have shown 
a negative correlation between BMD and insulin levels or insulin resistance as assessed by HOMA-IR in 
e.g. Brazilian subjects236. An inverse association between serum leptin concentration and BMD, adjusted 
for body mass, was detected in the same study indicating that leptin, insulin and HOMA-IR could be 
linked to bone metabolism in these subjects. However, this finding could not be repeated in another trial 
suggesting that serum leptin would not be a direct determinant of BMD at least in Chinese population237, 
and thus the role of leptin as a determinant of BMD-related parameters is not very conclusive, or the 
variability is dependent on ethnic factors.  
The dynamic role of OC as a potential mediator in these populations with mild hyperglycaemia has not 
been properly assessed. In a smaller Japanese study cohort (n=50 patients with poorly controlled T2DM) 
improvement of glycaemic control was associated with a decrease in BAP and an increase in total OC120. 
Changes in HbA1c were inversely associated with changes in OC, including the proportion of unOC in 
relation to total OC (unOC/OC), leaving space for speculation over the potential role of decreased unOC 
as a marker of improved, previously impaired bone formation. 
?
After?introduction?of?a?lifestyle?intervention?or?dietary?modification?
Peripheral glucose sensitivity and insulin secretion have been demonstrated to improve under strenuous 
or interval exercise238,239. Circulating insulin levels decline during physical exercise while insulin delivery 
is increased or at least maintained at the same level with increased skeletal muscle blood flow239. Also 
reduced burden of hyperlipidaemia favourably influences insulin signalling and glucose sensitivity240.  
The proposed correlation between TGs and OC or change in either parameter, has been reported with 
variable results; a negative association was induced with diet or diet plus resistance training intervention 
during which circulating levels of OC were associated with insulin sensitivity, mainly in lean subjects, 
and with insulin secretion170. Previous attempts to induce changes in levels of OC with caloric restriction 
have failed171 but potentially bone loading could lead to increased synthesis of OC; the question remains 
whether the proportions of carboxylated and uncarboxylated OC remain the same under loading. In 
another study, obese, but otherwise healthy, post-menopausal women undergoing a supervised 20-week 
weight loss program were studied to determine the associations between changes in total OC and degrees 
of carboxylation of OC and changes in body weight and percent body fat (BF%)241. All participants 
received supplemental Vitamin K, D and calcium over the 20-week intervention period. After loss of an 
average 10.9 ± 3.9 kg and 4% body fat, the serum concentrations of total OC, unOC, percentage of unOC 
and PINP did not significantly change, nor were these measures associated with changes in weight or BF% 
(all p=ns). These data do not support an association between OC and weight or BF% loss in post-
menopausal women supplemented with nutrients implicated in bone health241 and adds to the conflicting 
pool of evidence showing opposite results vs. other studies exploring the proposed hypothesis.  
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Vitamin K has been established to be a key player in carboxylation of OC131,136. No association between 
unOC and insulin resistance, as measured by HOMA-IR, has been demonstrated in studies with Vitamin 
K supplementation140,242.  
?
Bone?turnover?cycle?
In our ELLU study population, reduced OC but similar BAP baseline concentrations were reported for 
those subjects with a history of childhood obesity vs. their controls. Comparable findings were reported 
in a study addressing levels of BTM in T2DM compared to controls. Similarly, total OC was decreased 
and hydroxyproline, a component of collagen less frequently used as a resorption marker, was increased 
among subjects with T2DM compared to those without diabetes, whereas BAP concentrations did not 
differ between groups243. Even if our obese subjects were still considered normoglycaemic, they 
demonstrated early signs of insulin resistance, the most well-established determinant and driver of 
pathophysiology of T2DM in an obese population. Thus, based on the BTM pattern, the hyperinsulinemia 
and temporary hyperglycaemia may have affected different stages of the bone turnover cycle. These 
differences in BTMs may explain the general paradox of lower bone strength and increased BMD in 
T2DM, as markers of bone resorption and formation seem to be lower, whereas the mineralisation, which 
is reflected by BAP, is within normal limits or not different from the controls244,245. The lower bone 
turnover may not be coupled to a similar lowering in mineralisation, making the bone matrix 
hypermineralised, and leading to a more frail and almost osteopetrotic bone246. Thus, additional 
adjustment of BTM reference range data for metabolic factors and adiposity (BMI, body composition) 
but also exclusion of subjects with diabetes or glucose impairment provides the foundation for a more 
appropriate interpretation of the BTM results in apparently healthy subjects.  
?
Future?fracture?risk?and?BTMs?in?subjects?with?glycaemic?impairment?
In our obese subjects (ELLU cohort), the observed low bone turnover in relation to higher skeletal area 
in young subjects is an important finding as it may have multiple consequences, including an increased 
risk of future fractures. Increasing adiposity has been suggested as a risk factor for fracture in children, 
with247,248 or without fractures249, and low BMD, consistent with an increased fracture risk, has been 
observed in patients with T1DM250. BMD is considered as a golden standard for evaluating the risk of 
fractures in osteoporotic populations, while assessment of an amount of mineralised bone might be sub-
optimal for fracture risk assessment in subjects with glucose intolerance or diabetes. On the other hand, 
cross-sectional studies examining fracture risk and BTMs have been conducted with different outcomes; 
serum OC/BAP ratio has been shown to be inversely associated with the presence of vertebral fractures 
(OR=0.695, p<0.05) even after an additional adjustment for lumbar or FN BMD251. However, lack of 
glycaemic control and lower IGF-1 levels may cause osteoblast dysfunction independently of BMD and 
thus indirectly contribute to reduced bone quality and fractures. Reduced or low bone turnover, marked 
by decreased BTM levels such as IGF-1 or OC, or increased sclerostin levels, or combined low PINP 
and elevated CTX concentrations, are associated with vertebral fractures in T2DM252,253,254,255,256. 
Moreover, elevated u-NTX has been shown to be increased in insulin-treated women with T2DM and 
post-menopausal osteoporosis and a vertebral fracture257. Nevertheless, there is also increasingly 
opposite evidence highlighting the uncertainties regarding assessment of OC as a reliable marker in 
subjects with T1DM and long-term or insulin-treated T2DM with complications. Lack of association 
between OC and other BTMs and vertebral fractures have been published by many120,255,257,258,259. In 
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general, in subjects with insulin-treated diabetes any results should be interpreted with caution as 
especially IGF-1 levels may be altered due to insulin treatment and severity of diabetes.  
 
Risk?of?diabetes?during?or?after?use?of?anti?resorptive?therapy?
When reconsidering the original theory by Karsenty et al 132 regarding the role of bone in regulation of 
energy metabolism, one of the most striking consequences of the theory is the presumed increased risk 
of metabolic diseases due to use of anti-resorptive therapy. If initiation of bone resorption was crucial 
for conversion of OC into its uncarboxylated form, then therapy-induced suppression of bone turnover, 
e.g. with bisphosphonates, should lead to an increased risk of hyperglycaemia and secondary diabetes. 
However, none of the independent, pivotal osteoporosis trials, with detailed assessment of both skeletal 
and glycaemic parameters, have reported an increased risk of T2DM or any impediments in glucose 
tolerance after intervention with anti-resorptive therapies260. The same also applies to smaller studies in 
which OC and unOC and glycaemic parameters were assessed in detail in subjects receiving other drugs 
known to alter bone turnover, such as PTH or hormone replacement therapies261,262,263,264,265. 
Interestingly, data from the national Danish registry reported a reduced incidence of risk of diabetes in 
those on anti-resorptive therapy266, albeit the registry has no information about the OC levels of the 
targeted individuals. In conclusion, at least in humans, altering the rate of bone resorption either does not 
lead to a sufficient increase in circulating forms of unOC and/or the elevated unOC does not significantly 
influence glucose metabolism. 
?
11.4 The?role?of?OC?and?other?BTMs?in?healthy,?younger?subjects?
Age, height and weight, and even PTH and puberty, are independent determinants of serum and urinary 
OC levels during childhood and adolescence.  Other BTMs are expectedly influenced by age, sex and 
pubertal stage, as the peak concentrations of all BTMs, including OCs, followed the well-established 
pattern also shown by others88,89,90. Other variables, including key biochemical markers reflecting overall 
health status, seem to have no or limited impact on these BTMs. Similarly, and rather unexpectedly, 
DXA parameters show limited or no impact on the assessed BTMs. While in adults the BTMs mostly 
predict and reflect current BMD values, the ongoing rapid modeling process and thus elevated BTMs in 
children and adolescents potentially only predict their future, adult BMD status rather than correlate with 
a relatively random BMD value at a given time-point during a paediatric growth spurt. Consequently, 
BTMs indicate bone turnover at the time of evaluation while BMD is a marker of long-term effect 
reflecting the events of the preceding months or even years. 
 
Limited?paediatric?reference?data?available?
Our cohort contained a reasonably homogenous and representative group of young subjects with normal 
bone health, as indicated by reference BTMs89, and scattered over different stages of pubertal growth 
spurt. Most of the available paediatric BTM data and guidance for interpretation of the results in children 
and adolescents is only applicable to post hoc analysis of birth cohorts, different bone-derived diseases, 
osteoporosis or conditions inducing a secondary effect of glucocorticoid therapy on their bone 
health249,267,268,269,270,271.  In those populations, assessment of calcium, PTH and phosphate levels in 
relation to the BTMs has been demonstrated to be crucial for correct interpretation of impaired bone 
markers and metabolism in children and adolescents. In our cohort, only PTH, and not Vitamin D, along 
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with expected age, height and weight were assessed to be independent determinants of cOC. Thus, the 
role of biochemical markers, including calcium or phosphate levels in predicting OC concentrations 
seems limited in healthy subjects and only becomes more substantial if BTMs are used to assess skeletal 
health when preventing any secondary effects such as osteoporosis or growth hormone deficiency in 
paediatric cohorts. Our cohort additionally displays important and expected characteristics typical for a 
Finnish population, including low Vitamin D levels in midwinter samples, providing a platform and 
reference intervals for clinical interpretation of BTM results in corresponding subjects, with the seasonal 
midwinter nadirs. Statistically significant seasonal impact of variable Vitamin D concentrations on BTMs 
has been reported267 but the clinical relevance of such small effect size is questionable when assessing 
the BTM concentrations in healthy children and adolescence. 
 
Methodology??serum?or?urine?sampling??
When assessing any biological markers in healthy individuals, but also, in children and adolescence with 
chronic conditions requiring long-term monitoring, the preferred sampling method is non-invasive and 
pragmatic, such as urinary sampling as an alternative to serum sampling. Paradoxically, in our paediatric 
healthy cohort the urinary samples were missing more often than any of the serum samples (100% 
adherence to sampling); involuntary production of urine at any given time indeed seems challenging in 
all age categories from infants to the elderly.  
The mid-fragment OC, detectable in urine, reflects a different dimension of bone turnover, including 
resorption272 while it has also been demonstrated to be a marker of growth in a special population of 
prematurely born infants during their growth spurt in the postnatal period152. Our study results indicate 
that even if the urinary OC concentrations were comparable between sexes in younger age categories 
there was a limited correlation between serum OC and urinary OC, especially in younger boys, and these 
values were mostly driven by age categories, with progressively improving correlation with increasing 
age. This might not be a unique finding as comparisons in post-menopausal populations between other 
BTMs in both urine and serum have revealed that urinary co-efficients of variation may be twice as high 
as markers detectable in serum273. A preferred and holistic assessment of bone turnover in this population 
would be a combined assessment of several urinary bone turnover markers for reduction of the effect of 
variation within an individual sampling time and age category. Additionally, urinary markers depend on 
the amount of marker secreted during bone formation and released from bone during bone resorption. 
Therefore, they are not directly translatable into amounts of bone gained during a growth spurt while a 
simultaneous assessment of bone markers displaying both the rates of bone resorption and bone 
formation will provide a more reliable, composite result of the overall bone turnover. 
 
11.5 Validation??limitations?and?strengths?of?this?research?
The key strength of our chosen cohorts was that all the adult subjects were meticulously studied during 
the time when they were close to, or at the age of, their peak bone mass. The selection of these unique 
cohorts, especially the pooled population from Study I-II, provided an optimal platform to explore the 
alleged bi-directional regulation of energy metabolism without significant confounding factors. The 
methods also included a comprehensive analysis of bone metabolism by measuring multiple BTMs, 
targeting resorption and bone formation or its rate, and different forms of OC, cOC and U-mid-fragment 
OC, skeletal parameters by DXA, at various time-points during OGTT in obese young subjects or those 
born with VLBW vs. their carefully selected controls. Inclusion of these healthy populations without 
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substantial comorbidities and thus with special potential to confirm or reject the hypothesis regarding the 
presumed universal causality between bone turnover and energy metabolism, stood out as a novel and 
innovative study design. 
Based on the preclinical data, the changes in the metabolic pattern, the effect size and its timing in our 
human subjects became increasingly unclear. This was partially due to the chosen approach, evaluation 
of changes in energy load on OC (vs. OC knock-out in animal studies) but also, as a standardised OGTT 
did not allow us to study the continuous direct effects of glucose or insulin on bone metabolism. 
However, it is important to remember that also attempts to confirm the role of OC in glucose metabolism 
failed when clamp techniques were implemented208. We did not have access to direct measures of unOC 
but assessed total OC and cOC and estimated the biological activity of OC and indirectly the effect of 
unOC, based on these values. In our assay the slopes of the standard calibration curves for OC and cOC 
did not run in parallel and thus the estimated method, deduction of cOC from total OC concentration, for 
unOC may not be sensitive enough to detect small changes in the carboxylation status of OC. Further, 
we did not have data on vitamin K intake or vitamin K status, which is known to influence carboxylation 
of osteocalcin146. On the other hand, it is unlikely that any of our subjects had severe vitamin K deficiency 
since they were not on parenteral feeding or any other dietary restrictions. 
Feeding with an acute glucose dose gives rise to various carbohydrate-induced incretin hormones such 
as GIP and GLP-2, which might have partially confounded our findings for cohorts with OGTT. GLP-2 
has been identified to directly inhibit bone resorption194 and our results from all cohorts, without analysis 
of the incretin hormones, are aligned as the CTX values in particular were markedly suppressed during 
OGTT. A further limitation is that we measured only total adiponectin and not the isoforms, which 
associate more strongly with insulin resistance and metabolic syndrome. On the other hand, a 
standardized OGTT differs from a more physiological intake of nutrients, but otherwise corresponds to 
real life situation with an acute postprandial load, and thus represents the glycaemic variant of an exercise 
ECG: a stress-test of the metabolic response in an otherwise healthy body. 
The main weakness of our cohort with subjects with severe childhood obesity but also, the paediatric 
normal reference range study, was the limited overall number of subjects: for normal ranges a total of 
172 children and adolescents are less than recommended by international guidelines for validated 
assessment of reference intervals89. Specifically the low number of boys and in general, the partially 
uneven distribution of pubertal stages over the two sexes might explain the low correlation between the 
serum and urinary OC values.  On the other hand, we have established reference ranges in an otherwise 
representative cohort of healthy girls and boys, through different stages of puberty and an array of BTMs 
reflecting key dimensions of bone formation from childhood towards adulthood and peak bone mass. 
When defining reference ranges for local clinical implementation it is crucial for the cohort to display 
and mirror important and expected characteristics of a typical, in our case Finnish, population, including 
low Vitamin D levels collected in midwinter samples, providing therefore a platform and reference 
intervals for clinical interpretation of BTM results in corresponding subjects. 
All total OC and cOC samples were analysed with the same method, mostly by the same individuals 
holding the micropipettes. The analysis results can therefore be considered suitable to be explored from 
the perspective of a more generalised and composite analysis – the development of dynamics of OC 
concentrations over time spectrum and age categories from childhood to younger adult ages in apparently 
healthy individuals. 
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11.6 Conclusions?and?future?directions?
This research explored the concept of an assumed link between glucose and bone metabolism and 
whether it could be demonstrated in a population, which displayed weak signs of early insulin resistance 
and impaired glucose tolerance in early adulthood, in an apparently healthy VLBW cohort, or in obese 
young adults without diabetes vs. their controls. The purpose was also to evaluate if changes in glucose 
load were reflected in serum OC concentrations and its degree of carboxylation. Furthermore, normal 
paediatric reference ranges and their independent determinants for serum total, carboxylated and urinary 
mid-fragment OC were to be established. 
Based on the observations the following conclusions can be presented: 
1. A significant decrease in serum concentrations of both total OC and its carboxylated form, 
cOC, after oral intake of glucose resulted in rapid suppression of other BTM, and bone resorption 
and formation markers in all young adults.  
2.? Young, obese subjects with early signs of increased insulin resistance have lower 
concentrations of BTM, other than BAP, compared with normal weight subjects at baseline. The 
postprandial total OC was suppressed but the OGTT-induced effect appeared later and with 
reduced magnitude in obese subjects versus their controls.  
3. Energy metabolism evidently influences parameters of bone turnover but the direct role of 
insulin, as the mediator of these changes, needs further investigations: postprandial insulin did 
not associate with OC or cOC either before or after OGTT. 
4. Age, height and weight, and PTH and puberty, are independent determinants of serum and 
urinary OC levels during childhood and adolescence. In addition, all reference BTM followed the 
expected, puberty- and growth spurt-related patterns in our representative Finnish cohort of 
healthy children and adolescents.  
 
The most pragmatic and clinically applicable results of this thesis are unquestionably those related to the 
newly proposed BTM reference ranges in a representative Finnish cohort of healthy children and 
adolescents. These suggested reference ranges, applicable for growing children and adolescents, 7 to 19 
year-old boys and girls, and with only a limited number of independent determinants for the urinary, 
serum total and carboxylated OC levels, provide with a tangible tool for clinicians assessing the bone 
turnover in both healthy youngsters but also in those with impediments of bone health, with or without 
treatment.   
Our other results indicate that the accumulating evidence, including our involvement in the pool of 
systematically and objectively evaluated data in healthy humans, has weakened the hypothesis suggesting 
that OC is a key factor responsible for regulation of metabolic control or energy metabolism.  Whether 
this is mostly due to species-specific differences, which preclude the direct translation of the earlier 
findings from the animal models to humans, is not yet known. Alternatively, the original theory needs 
refining as also our research has contributed to the increasing wealth of less confounded evidence 
questioning the validity of the original hypothesis linking OC as a key player in energy metabolism.  
For clinical applicability, studies targeting the effect of therapeutically manipulated bone cells on glucose 
homeostasis (e.g. with both anti-resorptive or anabolic agents used in management of osteoporosis) or 
those changing the degree of carboxylation in a more physiological setting, as with the use of warfarin 
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or low vitamin K–containing diet, are still missing. The alleged role of OC in impaired glucose tolerance 
is additionally difficult to be studied in rodent models displaying hyperglycaemia and its consequences 
as the pathophysiological pathways leading to the complications of diabetes are different in humans vs. 
those observed in genetically engineered mice. It is also not feasible or ethical to mimic the knock-out 
design (vs. animal, mostly mice models) in humans and thus replication of the animal studies in human 
subjects cannot be completed. Therefore, the animal-derived data can only be hypothesis–generating 
while the exploration of the putative fundamental role of OC in energy metabolism must continue in 
human populations, which are preferably less burdened by confounding factors.  
Total OC is and remains a reliable biomarker of bone turnover in subjects of any age. Bone is in a constant 
state of turnover, and the entire skeleton is regenerated every 10 years. Therefore, it has been essentially 
impossible to distinguish the role of OC as an established marker of bone turnover from its potential role 
as a mediator of glucose metabolism through the use of secondary analysis of completed osteoporosis 
populations. Interestingly, the observed inverse association between the crudely assessed bone turnover 
and insulin resistance in diverse patient populations were immediately interpreted as direct evidence that 
unOC is indeed a hormone involved in human glucose metabolism. Independently, there has been 
unprecedented, inappropriate and surprisingly non-scientific use of causal language in citing results such 
that the different forms of OC have been used interchangeably in the literature even though only the 
unOC was found to have an effect in the original mouse model.  
As the scientific community is increasingly concluding, in line with our own findings, prospective 
clinical trials designed specifically to test the suggested bi-directional hypothesis are unquestionably 
required. Based on the evidence today, it is increasingly uncertain that OC or any biological form of it, 
such as unOC, has potential as a therapeutic target for regulation of glucose metabolism in humans.
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